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ABSTRACT
Adaptive designs can improve the efficiency of drug development, but further research is
needed before some are more widely implemented. One such design is a treatment-selection
design, which begins with k treatment arms, but only a subset is carried forward after an
interim analysis. The final analysis of the selected arm(s) is then performed using the data
from both stages of the study. One issue with this design is ensuring the Type I error rate
is controlled, but there have been a number of proposals that largely address this. A second
drawback that has not yet been fully addressed is that the maximum likelihood estimate of
the selected arm at the final analysis is often biased upward due to the selection method.
Unbiased estimators already exist for this design, but methods with an acceptable
balance between bias and mean squared error (MSE) are lacking. In this dissertation, two
estimation approaches are proposed. The first is a parametric bootstrap resampling method
in which the level of bias adjustment applied is driven by a comparison of the observed
results to those expected when all arms have equal true means. The second approach is
an empirical Bayes estimator that implements a novel limited translation function. These
methods are compared to previously proposed approaches with respect to bias and MSE
for studies that have either a normal or binomial endpoint.
Both proposed methods are shown to exhibit reduced bias with reasonable MSE in some
simulated scenarios, but the resampling method consistently shows similar, or improved,
performance compared to previous approaches across the examined scenarios. The utility
v
of this resampling method is further demonstrated by showing that it can be implemented
when the arm with the second largest mean is selected for stage 2. It is also shown
that the resampling method can be extended to when more than one arm is selected in
stage 1, when there is a futility analysis, or when the study has a time-to-event endpoint.
Recommendations on confidence intervals are also provided. The results demonstrate that
the parametric bootstrap resampling method is a viable estimation approach for treatment-
selection designs.
vi
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1Chapter 1
Motivation
The process of bringing a drug from the lab to a clinical trial and eventually to the market
is a process that is both costly and lengthy. The costs associated with bringing a drug
to the market is approximately $1 billion, and it takes an average of 9 years from the
time that the first human is dosed with a drug to the point when it is approved. In
addition, only about 1 out of every 6 drugs that are tested in a clinical trial actually gets
approved (Kaitin 2010). Given these hurdles, new approaches are sought to make the drug
development process more efficient by improving the probability of success and mitigating
both safety and financial risks.
Adaptive clinical trial designs are well-suited for improving this efficiency. These designs
allow for changes to be made to the study based on emerging data. Such adaptations include
sample size re-estimation based on data at an interim analysis (e.g. Cui et al. (1999) and
Mehta and Pocock (2011)), adjusting the randomization ratio to enroll more patients to
better-performing subgroups (e.g. Barry et al. (2014)), and identifying a biomarker-positive
subgroup of patients at an interim analysis and enrolling only biomarker-positive patients
for the rest of the study (e.g. Simon and Simon (2013) and Mehta et al. (2014)). There
are also adaptive dose-finding designs that allow for the addition of new arms based on
the performance of two initial arms (Chang and Wang (2014)). Other types of adaptive
designs have also been previously described (Chang (2014)). Yet another adaptive design is
a treatment-selection design (also called a “Pick-the-Winner” or “Drop-the-Losers” design)
in which patients are initially enrolled to one of k treatment arms. At a pre-specified interim
analysis, the arm (or arms) with the best response is selected to move on to the second stage
where subsequent patients are enrolled only to the selected arm(s) or a control arm, if one
exists. These designs can be implemented as a phase II/III design where stage 1 represents
the phase II study and stage 2 represents the confirmatory phase III study. Alternatively,
they can be used in phase II dose-finding studies, particularly in non-oncology settings.
2Treatment-selection designs can result in fewer enrolled patients and shorter timelines
since the data from patients enrolled in stage 1 can be combined with those in stage 2, and
sponsors avoid having to close one study and initiating another.
There have been a number of proposals for treatment-selection designs. Thall et al.
(1988) proposed such a design for binomial endpoints where patients were enrolled to one
of k experimental arms or a control arm in stage 1. One experimental treatment and the
control were carried forward to stage 2 only if the selected arm exceeded a pre-specified
threshold of activity above the control arm. The selected experimental arm was then
considered superior to control in stage 2 if it exceeded a second pre-defined threshold.
The number of patients enrolled to each arm in stage 1 (n1) and stage 2 (n2) and the
two thresholds were calculated to minimize the expected sample size under the following
conditions:
• the probability of moving to stage 2 and declaring an experimental arm superior to
the control was no more than α when all arms had equal true means
• the probability of moving to stage 2 and declaring an experimental arm superior to
the control was at least 1 − β under the least favorable configuration of the true
experimental means θ1, ..., θk.
This least favorable configuration was defined by the authors as the condition θ1 = ... =
θk−1 = θ0 + δ1 and θk = θ0 + δ2, where θ0 was the true mean of the control, θ0 + δ1
represented a marginal improvement over θ0, and θ0 +δ1 represented a clinically significant
improvement. It was shown that the power was minimized under this condition compared
to other values of θ1, ..., and θk−1. Thall et al. (1989) later modified this design by propos-
ing to enroll patients to the control arm only during stage 2 after one experimental arm
was identified to have sufficient activity compared to a historical estimate of the control
treatment. This was proposed for indications such as various cancers, where there was an
elevated probability of no arms being selected for stage 2.
Schaid et al. (1990) expanded upon the designs of Thall et al. to accommodate time-to-
3event endpoint. During the first stage, n1 patients were enrolled to k treatment arms. At
the interim analysis, those with a hazard ratio below a critical value C1 were discontinued.
If any treatments had a hazard ratio greater than a second critical value, C2, the study
stopped for overwhelming efficacy. Any treatments with a hazard ratio between C1 and
C2 continued to stage 2, along with the control. For each arm in stage 2, n2 additional
patients were enrolled and the final analysis was conducted after sufficient follow-up using
the Bonferroni correction to control α. The values of n1, n2, and C2 were identified such
that they minimized the expected total number of patients under the constraints of power
and α.
Stallard and Todd (2003) proposed a treatment-selection design where the best per-
forming treatment was selected at the first interim analysis, and then additional interim
analyses were subsequently conducted to compare the selected arm to the control arm. The
null hypothesis of no difference between experimental and control arms, H0 : θi − θ0 = 0,
was tested at analysis j using the score statistic
(
Z
(s)
j
)
based on information Ij . Group
sequential stopping rules were conducted using an alpha-spending function. They identi-
fied the distribution of Z
(s)
1 and Z
(s)
j given Z
(s)
j−1 and then iteratively identified upper and
lower boundaries uj and lj such that:
Pr(Z
(s)
j ≥ uj , Z(s)1 ∈ (li, u1), ..., Z(s)j−1 ∈ (lj−1, uj−1)|H0) = α(tj)− α(tj−1)
and
Pr(Z
(s)
j ≤ lj , Z(s)1 ∈ (li, u1), ..., Z(s)j−1 ∈ (lj−1, uj−1)|H0) = α(tj)− α(tj−1)
where tj was the information fraction at analysis j. The maximum information was set
such that the power was 1− β under the least favorable configuration.
Shun et al. (2008) explored treatment-selection designs that included two experimental
4arms and a control. They noted that the test statistic was:
ZS =
 Z1 if X1 > X2Z2 if X2 > X1,
where:
Zi =
θˆMLE,i − θˆMLE,0√
2σ2/(n1 + n2)
,
where θˆMLE,0 and θˆMLE,i were the maximum likelihood estimates of the control and ex-
perimental arms, respectively. They identified the exact distribution of ZS and determined
that it was not normally distributed. They showed, however, that it could be very well-
approximated by a normal distribution, which allowed for control of the Type I error,
sample size estimation, and point estimation.
The designs proposed by both Stallard and Todd and Shun et al. allowed for only one
treatment to be carried forward after selection, but this was extended by both Kelly et al.
(2005) and Stallard and Friede (2008). Stallard and Friede identified a group sequential
design that allowed for more than one arm to be carried forward and allowed for multiple
selection time points. They showed that when the number of arms carried forward at
each analysis was pre-specified, then the type I error rate was strongly controlled. When
the number of arms was data-driven, they showed that defining the critical boundaries as
if the number of arms was pre-specified was a reasonable approach, and actually led to
conservative boundaries in many instances.
Wu and Zhao (2012) also proposed a design where multiple arms could be carried for-
ward after the selection time point. They used a selection rule where, for two experimental
arms and a control, if:
• X1 −X2 > δ, then arm 1 was selected (This decision was referred to as A1)
• X1 −X2 < −δ, then arm 2 was selected (A2)
• |X1 −X2| < δ, then both arms were selected (A3).
5In the above, X1 and X2 were normally distributed with means θ1 and θ2, respectively,
standard error σ2/n, and known σ2. Let:
Zi =
θˆMLE,i − θˆMLE,0√
2σ2/(n1 + n2)
be the test statistics comparing arm i to the control at the end of the study. They identified
the conditional distribution of Zi under each condition, which differed based on whether the
global null hypothesis, θ1−θ0 = θ2−θ0 = 0, was tested or the individual null hypothesis was
tested. Using the appropriate distribution, they found the critical value Zα that controlled
the type I error rate, where separate values were calculated depending on whether A1, A2,
or A3 occurred. In the instance where A3 occurred, they recommended either a closed
testing procedure or using Hochberg’s sequential testing to adjust for multiplicity.
Ivanova et al. (2012) proposed a treatment-selection design specifically intended for
phase 2 dose-finding studies in non-oncology indications with endpoints that had either
a normal or binomial distribution. They used a Bayesian approach whereby the stage
1 data was used to update a conjugate prior distribution. Using Gibbs sampling, they
then constrained the stage 1 posterior distribution of each arm to meet an assumed dose-
response relationship. For example, they looked at the scenario where increasing doses
yielded increased efficacy to identify the minimum effective dose compared to a placebo.
They also examined the scenario where it was of interest to find the dose that maximized an
umbrella-shaped utility function. This utility function struck a balance between the adverse
events and efficacy observed at each dose. In each of these scenarios, stage 2 patients were
then enrolled to each dose in a manner proportional to their posterior probability of being
the optimal dose. The final dose was then selected after the posterior distribution had
been updated with the stage 2 data.
In their draft guidance on adaptive designs, the FDA (Food and Drug Administration
(2010)) classified treatment-selection designs as a “less well-understood” design, and this
was largely due to two issues with these designs. The first was in defining how to control
6the type I error rate. For treatment-selection trials that were group sequential in nature,
the approaches described above could address this issue. When there was only one interim
analysis, it has been proposed that combination tests be used, where the stage 1 p-value
(p) was combined with the p-value (q) that was based only on the stage 2 data. This class
of test included the Fisher combination test:
C(p, q) = pq,
the sum of the p-values (Chang (2007)):
C(p, q) = p+ q,
and the weighted inverse normal probability:
C(p, q) = 1− Φ[vφ−1(1− p) + wφ−1(1− q)]
where v and w were pre-defined weights such that v2 + w2 = 1, and they were typically
set such that v2 = n1n1+n2 and w
2 = n2n1+n2 . Bauer and Kieser (1999) proposed using
combination tests to combine the stage 1 and stage 2 p-values in a study design where the
selection method was not necessarily pre-defined or there was sample size re-estimation
for stage 2. They outlined an approach for setting the critical values for testing both the
global null hypothesis and the individual null hypotheses. Hommel (2001) later generalized
these results.
Proschan and Dodd (2014) proposed another hypothesis testing approach that simula-
tions indicated likely controlled the familywise error rate. They proposed a design where
patients were enrolled to one of k experimental arms or one control arm. An arm i was
dropped at the interim analysis if:
Zi =
Xi −X0√
2σ2/n1
< 0
7and any arm that exceeded that threshold continued to stage 2. If the standard Bonferroni
approach were used, then the adjusted critical p-value would be set at α/k. Proschan and
Dodd investigated whether the stringency could be reduced by instead using a critical p-
value of α/l, where l was the number of arms that moved on to stage 2. Simulations showed
that this approach did not control the familywise error rate, so they instead proposed
setting the critical p-value as α′/l, where α′ was lower than α. They proposed examining
all possible values of l between 2 and k, and for each value, they identified α′l that controlled
the familywise error rate under the global null of equal means. They then set α′ = α′min
to be the smallest observed α′l value. For the l arms that moved forward to stage 2, their
p-values were ordered such that p(1) < ... < p(l). They then implemented the following
sequential approach:
• If p(1) > α′min/l then no arms were deemed significant. Otherwise, the first arm was
deemed significant and the next arm was tested.
• If p(2) > α′min/(l − 1) then no further testing was conducted. Otherwise move on to
the next arm.
• This process was repeated until all arms were tested or one arm failed to meet the
significance criteria.
While they could not provide a proof that this approach strongly controlled the familywise
error rate, their simulation results indicated that it was highly likely that it was true.
While there have been several solutions proposed for adjusting the Type I error rate of
a study with treatment-selection, the second issue raised by the FDA guidance is still an
open area of research: estimation bias. Because the decision on whether a treatment arm
was carried forward to stage 2 was driven by it having one of the largest observed means
in stage 1, Bauer et al. (2010) described how the maximum likelihood estimate (MLE) of
the selected arm (both stage 1 and stage 2 data combined) often suffered from two types
of bias. The first type, termed “selection bias”, was the positive bias of the selected arm
8that arose due to the selection method. It was defined as:
Bsel(θ) =
k∑
i=1
E
[
θˆMLE,S − θi|θˆMLE,S = θˆMLE,i, Xi = X(1)
]
∗
Pr
(
θˆMLE,S = θˆMLE,i, Xi = X(1)
)
,
where X(1) was the maximum value. They showed that when the true treatment effects
of all arms were equal, the selection bias of the final estimate increased as the timing of
the interim analysis occurred later in the study. In this scenario, the stage 1 estimate
was always biased (regardless of the selection time) since the largest stage 1 mean was the
one selected. When the interim analysis was early, however, the final estimate was driven
largely by the unbiased stage 2 estimate, which minimized the impact of the stage 1 bias.
The authors also showed that the selection bias increased as the number of treatment arms
increased. This occurred because including more arms in stage 1 required the selected arm
to generally have a higher mean in order to surpass the means of the other arms. With
fewer arms, the probability of an arm being selected was higher and would not necessarily
require such a large mean.
Bauer et al. termed the second type of bias as “reporting bias”. This was the bias that
stemmed from the fact that the sample size was driven by the data and arose even when
the results from all arms were reported. It was defined as:
Brep(θ) = E
[
θˆMLE,i − θi|Xi = X(1)
]
Pr
(
Xi = X(1)
)
+
E
[
Xi − θi|Xi < X(1)
]
Pr
(
Xi < X(1)
)
.
This second type of bias was unconditional on both the order statistics and which arm
was selected for stage 2. When the true treatment effects of all arms were equal, the
mean reporting bias across all arms was negative, but it approached zero as the number of
arms increased and the selection time occurred later in the study. Note that if there was
no interim analysis for treatment selection, the values of Xi would be unbiased. As the
9number of arms increased in a treatment-selection design, the probability of each arm being
selected for stage 2 would decrease, so the expectation of the Xi values would approach the
true mean. If there were a limited number of arms, the estimates for the arms not selected
were more likely to be underestimates of the true mean.
Although the pharmaceutical industry is often more focused on controlling the Type
I error than estimation, the impact of estimation should not be overlooked. The ICH E9
guidelines (International Conference on Harmonisation of Technical Requirements for Reg-
istration of Pharmaceuticals for Human Use (1998)) outlined the importance of adjusting
for any known biases to ensure that valid conclusions can be made. The FDA’s guidance
on adaptive designs also explicitly stated that adaptations that allowed for selection of
treatment arms might lead to a random high. While much of their concern with the bias
was its impact on the Type I error, the guidance also pointed out that even if the Type
I error was controlled, any bias in the effect estimate had an impact on the risk/benefit
ratio and needed to be addressed.
Given the weight attached to accurate estimation by various guidances, improved esti-
mators are needed to minimize estimation bias in treatment-selection designs. One option
could be to base the estimation only on the stage 2 data. Particularly when there was only
one experimental arm carried forward to stage 2, the estimate based only on the stage 2
estimate was unbiased for the true mean of the selected arm. This, however, would be
an inefficient estimator as it would typically be underpowered to detect that effect size.
Increasing the size of the stage 2 portion of the study would defeat the purpose of using
a treatment-selection design. Alternative estimation approaches that allow for the com-
bining of data from both stages, but also adjust for the bias in the stage 1 estimate, are
needed. The next section describes a few approaches that have been previously proposed,
but the focus of this dissertation is on finding new estimators that reduce the bias while
maintaining a reasonable mean square error in treatment-selection designs.
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Chapter 2
Estimation in Treatment-Selection Designs: Previous Research
2.1 Normal Endpoints
Over the past several years, there have been a few approaches proposed to adjusting the
selection bias described by Bauer et al. Putter and Rubenstein (1968) explained that there
was no unbiased estimator for the selected arm based only on the stage 1 data. A proof of
this was later provided in Stallard et al. (2008). Conditionally unbiased estimators (given
the selected treatment arm) have instead been proposed for two-stage designs. A uniformly
minimum variance conditional unbiased estimator (UMVCUE) for the mean of the largest
of k treatment groups in a two-stage treatment selection design was first identified by Cohen
and Sackrowitz (1989), where they assumed that the selection time point occurred halfway
through the study. Let θ = (θ1, θ2, ..., θk), and X = (X1, X2, ..., Xk) where Xi ∼ N(θi, 1),
XS = X(1) = max(X) and Y ∼ N(θS , 1). Let Q be the order statistics of the stage 1 means.
For simplicity, assume Q was the event {X : X1 > X2 > ... > Xk}, so the order statistics
were the same as the arm indices. The Lehmann-Scheffe and Rao-Blackwell theorems were
leveraged to identify an unbiased estimator of θS = θ1 using (Y |X,Q). They accomplished
this by first identifying the joint distribution of X and Y given Q, (X, Y |Q), and converting
that to the joint distribution of Z and X given Q, followed by the joint distribution of Z
and XC given Q:
f(Z,XC |Q) =
∫ ∞
x2
f(Z,X|Q)dx1
= K−1(θ)
1√
2
φ
(
z − 2θS√
2
)(
1− Φ(
√
2(x2 − z/2))
) k∏
i 6=S
φ(xi − θi)IQ(x),
(2.1)
where Z = XS + Y , X
C = (X2, ..., Xk), K(θ) = Eθ[IQ(x)] and IQ(x) was the indicator
function for the event {X : X1 > X2 > ... > Xk}. Using this, they noted that (Z,XC) was
a complete sufficient statistic for θ, and derived the distribution of the unbiased value Y
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conditional on this complete sufficient statistic and Q:
f(Y |Z,XC ,Q) = f(X,Y |Q)
f(Z,XC|Q)
=
√
2φ(
√
2(y − z/2))
1− Φ(√2(x2 − z/2))
I(y ≤ z − x2)
Finally the UMVCUE was identified as:
E[Y |Z,XC ,Q] =
∫ z−x2
−∞
yf(Y |Z,XC ,Q)dy
= Z/2− φ(
√
2(Z/2−X2))√
2Φ(
√
2(Z/2−X2))
(2.2)
In this setting, Z/2 was the MLE, so E[Y |Z,XC ,Q] was interpreted as the MLE after a
correction factor was subtracted. Cohen and Sackrowitz also proposed a UMVCUE when
the variances of the arms were equal but unknown.
Since the assumption of the UMVCUE in (2.2) was that the variances were equal (i.e.
σ2
n1
= σ
2
n2
= 1), this implied that the selection must occur at 50% information to use the
estimator. Bowden and Glimm (2008) extended this estimator by allowing for the variances
to differ among the arms. Their estimator also allowed for selection of the jth largest stage
1 mean, where j may not equal 1 (i.e. the largest mean). Let σ21 =
σ2
n1
be the variance of
the first stage data in each arm and σ22 =
σ2
n2
be the variance of the second stage data in
the selected arm. Using a similar approach to Cohen and Sackrowitz, they identified the
joint distribution of Y and X given Q as the product of location-scale families:
f(Y,X|Q) = K−1(θ) 1
σ1
φ
(
xj − θj
σ1
)
1
σ2
φ
(
y − θj
σ2
)
IQ(x)
k∏
i=1,i 6=j
1
σ1
φ
(
xi − θi
σ1
)
They then substituted Y with Z that to form the joint distribution of Z and X given Q,
where now Z = σ2σ1Xj +
σ1
σ2
Y :
f(Z,X|Q) = K−1(θ)φ
(
z − θjα1,j√
σ1 + σ2
)
1
σ21
φ
(
xj − Zα1,j
σ1
σ2
α2,j
)
IQ(x)
k∏
i=1,i 6=j
1
σ1
φ
(
xi − θi
σ1
)
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where α1,j =
σ1
σ2
+ σ2σ1 and α2,j =
σ22√
σ21+σ
2
2
. They then formed the joint distribution of Y ,
Z, and XC given Q:
f(Y,Z,XC |Q) = K−1(θ)φ
(
z − θjα1,j√
σ1 + σ2
)
1
σ22
φ
(
y − Zα1,j
α2,j
)
IQ(x)
k∏
i=1,i 6=j
1
σ1
φ
(
xi − θi
σ1
)
They then identified the distribution of Y given XC , Z, and Q:
f(Y |XC , Z,Q) = f(Y,X
C , Z|Q)
f(XC , Z|Q)
and took the expectation to get the estimator:
θˆBG,S = E[Y |XC , Z,Q] = θˆMLE,S − σ
2
2
σ21 + σ
2
2
φ(Wj,j+1) + φ(Wj,j−1)
Φ(Wj,j+1) + Φ(Wj,j−1)
where Wu,v =
1
σ21
(
σ22X(u)+σ
2
1Y√
σ21+σ
2
2
−X(v)
√
σ21 + σ
2
2
)
This estimator did not work if the treat-
ment selection occurred at the end of the study (i.e. no interim analysis was conducted),
as the estimator relied on the unbiased mean in the second stage.
There were a couple of downsides to the UMVCUE. The first was pointed out by Cohen
and Sackrowitz, which was the fact that the UMVCUE depended only on the selected arm
and the arm with X(2). As a result, information was ignored when k > 2. Another
drawback was noted by Bowden and Glimm in that the UMVCUE had very high MSE
when the true treatment means were all equal. This has led others to look for estimators
that allowed for a small amount of bias in exchange for more reasonable MSE.
Whitehead (1986) noted that group sequential designs with two arms yielded biased
estimates due to the repeated testing, and proposed that a better estimator was:
θ˜ = θˆMLE −B(θ)
where B(θ) was the bias of the standard MLE. Because B(θ) was unknown, he proposed
instead estimating the bias relative to an adjusted MLE, B(θ˜), using the Newton-Raphson
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algorithm.
Stallard and Todd (2005) expanded upon this approach for use in the group sequential
design with treatment selection discussed in Stallard and Todd (2003) and extended the
iterative approach to include all arms. They noted that the score statistic at the first
interim analysis for the ith treatment arm, Z
(s)
i,1 , was normally distributed with mean θiIi,1
and variance equal to the Fisher information, Ii,1, but that the score statistic for the
selected arm, Z
(s)
S,1, was not normally distributed. They identified the joint distribution of
Z
(s)
S,1 and S given IS,1 and then the distribution of the subsequent test statistics for the
selected arm, Z
(s)
S,j , and S given IS,j . For a trial that stopped at the J
th interim analysis,
they derived the expectation of the MLE of the selected arm, θˆMLE,S = Z
(s)
S,τ/IS,J , as well
as the MLE of the arms not carried forward to stage 2. Since the bias of the selected arm
was driven in part by the true means of all treatment arms, they proposed that a bias-
adjustment estimator should account for all arms. Let B(θ) be the vector of bias values
for each arm:
Bi(θ) = E[θˆMLE,S ]− E[θS ], i = S
and
Bi′(θ) =
E[Z
(s)
i′,1|S = i]
Ii′,1
− θi′ , i′ 6= S
where θ = (θ1, ..., θk). The vector B(θ) was approximated iteratively by B(θ˜) in a manner
similar to that described in Whitehead (1986). They then proposed the vector of adjusted
estimates at the rth iteration to be:
θ˜(r) = θˆ −B
(
θ˜(r−1)
)
.
Drawbacks of this, however, included computational intensity and the fact that the algo-
rithm did not always converge to provide an estimate.
While the above methods used iterative approaches to estimate the bias, there was
another class of estimators that was shown to improve upon the UMVCUE by decreasing
14
the MSE with only a small increase in the bias. Let X = (X1, ..., Xn) be the observed data
where Xi ∼ N(θ, σ2). Stein (1956) noted that the MLE, θˆ = θˆMLE,S = X, was inadmissible
with respect to the quadratic loss function, L(θ) = (θˆ − θ)2 when n > 2. James and Stein
(1961) then proposed the following estimator:
θˆSJ = X
(
1− (n− 2)σ
2∑
(X2i )
)
.
They showed that, for all values of θˆi when n > 2, this James-Stein estimator had uniformly
lower risk (MSE) compared to the MLE:
E[L(θ, θˆJS)] > E[L(θ, θˆMLE)]
This was termed a shrinkage estimator because it “shrank” the estimates towards 0. Since
James and Stein first proposed their estimator, there have been a number of modifications.
The James-Stein estimator could also be interpreted from a Bayesian perspective, as
discussed in Efron and Morris (1972). Let the prior for θ be N(µ, τ2). The posterior
distribution was then:
(θ|X) ∼ N
(
τ2
σ2 + τ2
X +
σ2
σ2 + τ2
µ,
σ2τ2
σ2 + τ2
)
∼ N
((
1− σ
2
σ2 + τ2
)
X +
σ2
σ2 + τ2
µ,
σ2τ2
σ2 + τ2
)
It could be shown that (n−2)σ2/∑(Xi)2 was an unbiased estimator of σ2/(σ2 +τ2). Since
the data was used to estimate the posterior density, this was an example of an empirical
Bayes estimator. When µ = 0, this empirical Bayes estimator was equivalent to the James-
Stein estimator. It was discussed in Casella (1985) that even if the prior parameter µ was
unknown, then the empirical Bayes estimator still had lower MSE than X when n > 3. Due
to their reduced MSE values, shrinkage and empirical Bayes estimators were potentially
well-suited for treatment-selection designs.
After providing a proof that the bias of the MLE was largest when the treatment
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arms were equal, Carreras and Brannath (2013) applied a modified James-Stein shrinkage
estimator that was proposed by Lindley (1962) to treatment-selection designs. They used
this to adjust the stage 1 mean of the selected arm based on all observed stage 1 means
when k ≥ 4. If the observed means were all relatively similar to one another, the shrinkage
estimate of the selected arm approached the overall grand mean: X =
∑k
j=1Xj
k . Conversely,
large differences among the stage 1 means placed more weight on the observed mean of
the selected arm, XS . So at the interim analysis, the adjusted stage 1 estimator, θˆ
1
L,S , was
defined as:
θˆ1L,S = Cˆ+XS + (1− Cˆ+)X
where:
Cˆ+ = max(Cˆ, 0) with Cˆ = 1− (k − 3)σ
2
n
∑k
j=1(Xj −X)2
.
After the interim analysis, n2 patients were then enrolled to the selected arm, and the
unbiased mean of the n2 patients, Y , was calculated. The combined results from the
two stages were calculated in the same manner as the MLE, with the exception that the
shrinkage estimate replaced XS :
θˆCB,S =
n1
n1 + n2
θˆ1L,S +
n2
n1 + n2
Y = tθˆ1L,S + (1− t)Y
Previously, Hwang (1993) had shown that, when the best arm was selected at the end
of a study, Lindley’s estimator (QL,S) was equivalent to the Bayes estimator of θS , and it
was a uniform improvement over the MLE with respect to Bayes Risk:
Rµ,τ (QL,S) =
∞∫
−∞
· · ·
∞∫
−∞
Eθ
{
(QL,S − θS)2
}
φ
(
θ1 − µ
τ2
)
· · ·φ
(
θk − µ
τ2
)
dθ1 · · · dθk.
This was applicable to all priors that were iid normal, θi ∼ N (µ, τ). Carreras and Bran-
nath extended this work to show that this domination property still existed for Lindley’s
estimator in two-stage treatment selection designs.
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Carreras and Brannath also showed through simulations that when there were no dif-
ferences among the true means, the shrinkage estimator showed considerably reduced bias
and MSE over the MLE. While the UMVCUE of Cohen and Sackrowitz was unbiased,
Carreras and Brannath confirmed it had much higher MSE than the MLE, particularly at
later interim analyses. They also showed that the estimator of Stallard and Todd (2005)
tended to overcorrect for the bias in this scenario and also had MSE that was generally
higher than the MLE. When only one treatment arm was effective, however, Lindley’s
method over-corrected for the bias and was the least accurate estimator.
When there were fewer than four treatment arms, Carreras and Brannath recommended
using the best linear unbiased predictors (BLUPs) from a random-effects model where the
treatment arm assignments were the random effects:
θˆi = µ+ αi
In this model, µ was the overall grand mean and αi was the random effect from the i
th
treatment arm. This was equivalent to replacing the term k − 3 in Cˆ+ with k − 1. When
only three treatment arms were considered, the results of the BLUP relative to the other
estimators were similar to those observed with Lindley’s estimator.
More recently, Bowden et al. (2013) proposed several empirical Bayes estimators that
borrowed from meta-analysis approaches to incorporate the information from both stages
of a treatment-selection design. The estimators assumed a prior distribution for the true
underlying mean θi ∼ N(µ, τ2), which led to a posterior expectation of:
E
[
θi
∣∣∣θˆMLE,i] = τ2
Wi + τ2
θˆMLE,i +
Wi
Wi + τ2
µ
where Wi = σ
2/n1 if i 6= S and Wi = σ2/(n1 + n2) if i = S. The general form of their
proposed estimators for the selected arm was not unlike other empirical Bayes estimators
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in that they attempted to estimate the posterior expectation:
θˆEB,S = Bˆ+S θˆMLE,S + (1− Bˆ+S)µˆ
where Bˆ+S = max{0, 1− CˆS}. The two proposed approaches differed in how µˆ and τˆ2 were
estimated and how CˆS was calculated, and both approaches were adapted from Carter and
Rolph (1974). The first was called the standard prior approach, whereby the estimate for
τ2 (referred to as τˆ2PM ) was the value that solved Q(τ
2) = k − 1, where:
Q(τ2) =
k∑
i=1
V −1i (θˆMLE,i − µˆ(τ2))2,
Vi = Wi + τ
2,
and
µˆ(τ2) =
∑k
i=1 V
−1
i θˆMLE,i∑k
i=1 V
−1
i
.
With this approach, Q(τ2) was the same as the generalized Q statistic used in meta analyses
(Viechtbauer (2007)), and this method for estimating µ was analogous to the random-effects
estimate of a meta analysis. The shrinkage factor, CˆS was then calculated as:
CˆS =
(k − 3)WS
(τˆ2PM +W )Q(τˆ
2
PM ) + (k − 3)(WS −W )
where W = (
∑k
i=1Wi)/k.
The second approach proposed by Bowden et al. was called the proportional prior ap-
proach, and it assumed a slightly different prior whereby θi ∼ N(µ,Wiτ2), which assumed
a different prior for each arm. This made the posterior expectation:
E
[
θi
∣∣∣θˆMLE,i] = τ2
1 + τ2
θˆMLE,i +
1
1 + τ2
µ.
The prior mean was still estimated as above, but since the τ2 terms now cancelled out, it
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was equivalent to calculating the mean when τ2 = 0:
µˆ(τ2) = µˆ(0) =
∑k
i=1 V
−1
i θˆMLE,i∑k
i=1 V
−1
i
=
∑k
i=1W
−1
i θˆMLE,i∑k
i=1W
−1
i
With this prior, the estimate of µ was analogous to the fixed-effect approach used in meta
analyses. The shrinkage factor was then calculated as:
Cˆ = Cˆ(0) =
k − 3
Q(0)
where Q(0) was Cochrane’s heterogeneity statistic, which was a test of the between-study
variation used to derive the DerSimonian and Laird estimator for τ2 in a meta analysis
(DerSimonian and Kacker (2007)). Q(0) was calculated to be the value of Q described
above when τ2 = 0. This estimator was then extended to limit the distance it was allowed
to deviate from θˆMLE,S (referred to as limited translation) by constraining Cˆ(0) to:
Cˆ(0) = min
{
k − 3
Q(0)
,
√
WS
|µˆ(0)− θˆMLE,S |
}
They compared these methods, among others, to that of Carreras and Brannath, which
was a shrinkage estimator of only the stage 1 data, but none were dominant over the rest.
They did note, however, that the proportional prior approach with limited translation
performed consistently well with respect to bias and MSE.
2.2 Binomial Endpoints
A uniformly minimum variance unbiased estimator (which was not conditional) for use
in treatment-selection designs with binomial endpoints was identified by Tappin (1992).
She used a similar approach to that used by Cohen and Sackrowitz, but she noted that
special attention needed to be paid to how ties were handled. When ties were broken
by selecting the treatment arm with the lowest index, she noted that the set of observed
responses (X1, ..., Xk, Y ) and their order statistics, Q, were complete sufficient statistics
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for the true proportions θ1, ..., θk. Here, Xi and Y were the number of observed responses,
and Q = (i1, ..., ik) represented the indices of the arms at the end of stage 1 after they had
been ordered by the number of responses from largest to smallest. She noted that Yn2 was
an unbiased estimator of θS and found the joint probability mass function of (Z,X
C , Q)),
where Z = X(1) + Y . Leveraging the Lehmann-Scheffe and Rao-Blackwell theorems, she
then found the UMVUE to be:
θˆT,S = E
[
Y
n2
∣∣∣∣Z,XC , Q]
=

Z
n1+n2
if Z −X(2) > n2
1
n2
∑Z−X(2)
Y=0 Y (
n2
Y )(
n1
X(1)
)∑Z−X(2)
Y=0 (
n2
Y )(
n1
X(1)
)
if Z −X(2) ≤ n2 and i1 < i2
1
n2
∑Z−X(2)−1
Y=0 Y (
n2
Y )(
n1
X(1)
)∑Z−X(2)−1
Y=0 (
n2
Y )(
n1
X(1)
)
if Z −X(2) ≤ n2 and i1 > i2.
where i1 and i2 were the indices of the arms with the largest and second largest stage 1
means, respectively.
Tappin also noted that when ties were broken by randomly selecting an arm, there was
no complete sufficient statistic for θ1, ..., θk, and therefore, there was no UMVUE. This was
due in part to the fact that breaking ties in this manner resulted in the complete sufficient
statistics requiring an additional parameter, Pr(S = i1|X). Under this condition, she
did identify an estimator that was uniformly minimum variance among invariant unbiased
estimators (UMVIUE). She also showed that when k = 2, this UMVIUE was minimax
among unbiased estimators and recommended use of this estimator over the UMVUE when
there were only two arms. She pointed out, however, that, in general, both estimators had
risk functions with poor properties and suggested that a Bayesian estimator would be
preferable.
Estimation in the situation where there were only two arms was further examined by
both Shen (2001) and Luo et al. (2010). Shen identified the distribution of θˆS − θS where
θˆS was the observed proportion of the selected arm and θS was the true proportion of the
selected arm. This was derived under the assumption that θˆ1 and θˆ2 were approximately
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normal, and the expectation under this distribution was found to be:
E[θˆS − θS ] = σ
2
1 + σ
2
2√
2pi(σ21 + σ
2
2)
exp
{
− (θ1 − θ2)
2
2(σ21 + σ
2
2)
}
where σ2i =
θi(1−θi)
n1
. Because the MLE of this expectation tended to underestimate the true
bias, he proposed a ”Stepwise Over-Correction” approach where the bias was calculated
as:
b̂ias(θS)γ =
√
(σˆ21 + σˆ
2
2)√
2pi
exp{−((i− 1)γ)2/2}
where:
(X1, X2, σˆ
2
1, σˆ
2
2) ∈ Ai, i = 1, 2, ...
and
Ai =
{
(X1, X2, σˆ
2
1, σˆ
2
2) : (i− 1)γ ≤
|θˆ1 − θˆ2|√
(σˆ21 + σˆ
2
2)
< iγ
}
.
This was a modified expression for E[θˆS − θSˆ ], and it was recommended that the tuning
parameter, γ, be set to 2. Smaller values of γ converged to the bias calculated using the
MLE of E[θˆS − θSˆ ], while large values converged to the overall maximum bias across all
values of θ1 and θ2. The adjusted value of θˆS was then calculated as tXS + (1 − t)Y −
t
(
b̂ias(θS)γ
)
.
The result of this approach was that the estimate over-corrected for the bias since the
estimate was set to be the maximum bias within the region Ai. Since the step function
was always greater than or equal to the true bias, it was a conservative approach. The
variance of the distribution of θˆS−θSˆ could be estimated and then used for the calculation
of confidence intervals with reasonable coverage probabilities. Shen also extended the
approach to the situation where there were more than 2 arms.
Luo et al. focused only on designs with two arms in the context of rare diseases where
patients were limited, and they identified an estimator using the method of conditional
moments. Using the work of Sill and Sampson (2009), they used the conditional distribution
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of XS + Y given the index of the selected arm and the number of responses in the non-
selected arm, and set the expectation of this distribution to XS+Y , so E[XS+Y |i1, X(2)] =
XS + Y .
They built upon the work of Kendall and Stuart (1963) and found the first conditional
moment of XS − n1θS given i1 and X(2) to be:
∆ = E
[
XS − n1θS |i1, X(2)
]
=
n1∑
j=a(i1,X(2))
(j − n1 ∗ θS) Tj(i1, θS)
V (i1, X(2), θS)
where:
Tj(i1, θS) = Pr(XS = j|i1 = s) =
(
n1
j
)
θjS(1− θS)n1−j
V (i1, θS) = Pr(XS ≥ a(S,X(2))|i1 = s) =
n1∑
j=a(i1,X(2))
Tj(i1, θS)
a(i1, X(2)) =
 min{υ : υ ≥ X(2)}, if s = 1min{υ : υ > X(2)}, if s = 2.
This yielded E[XS |i1, X(2)] = E[XS−n1θS |i1, X(2)]+n1θS = ∆+n1θS . They then proposed
their estimator to be the value of θS that solved the equation:
(n1 + n2)θS + ∆ = XS + Y
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Chapter 3
Overview of Simulation Studies
3.1 Normal Endpoints
To evaluate the estimators proposed here and compare them to previously described ap-
proaches, a number of simulation studies were conducted. Let Xi ∼ N
(
θi, σ
2/n1
)
, i =
1, ..., k, be the random variable representing the mean outcome from treatment arm Ti.
For the purpose of simplicity, σ2 was assumed known and equal to 1. An interim analysis
was conducted once n1 patients were enrolled to each arm in the first stage, at which point
all treatment arms were ordered based on their observed means, X(1) > X(2) > · · · > X(k).
Unless otherwise stated, and without loss of generality, the treatment arm with the largest
mean (i.e. XS = X(1)) was selected and carried forward to stage 2. Let Y ∼ N
(
θS , σ
2/n2
)
be the random variable representing the mean outcome in the n2 patients enrolled to TS
during the second stage of the study. At the final analysis, the estimated mean of TS , θˆS ,
was calculated using data from all n1 + n2 patients. Study designs with k = 3, 4, and 5
treatment arms were examined under four scenarios that largely captured the spectrum
of scenarios encountered when conducting in treatment-selection designs. For simplicity,
many of the subsequent results focused on k = 3 and k = 5. For these two values of k, the
scenarios examined were:
• Scenario 1 (“Equal Means”): θ = (0.4, 0.4, 0.4) or (0.4, 0.4, 0.4, 0.4, 0.4)
• Scenario 2 (“Linear Means”): θ = (0, 0.2, 0.4) or (0, 0.1, 0.2, 0.3, 0.4)
• Scenario 3 (“Two Active Arms”): θ = (0, 0.4, 0.4) or (0, 0, 0, 0.4, 0.4)
• Scenario 4 (“One Active Arm”): θ = (0, 0, 0.4) or (0, 0, 0, 0, 0.4)
Note that the Two Active Arms and One Active Arm scenarios were also examined for
k = 2.
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The value of the selection time, t = n1n1+n2 , ranged from 0.1 to 1.0, and a total of 10,000
simulations were generated for each value of t within each scenario. A total of n1+n2 = 100
patients were enrolled to the selected treatment arm TS . This was chosen because in a fixed
design with two arms, 100 patients per arm, and σ2 = 1, there would be 80% power to
observe a mean difference of 0.40.
For each value t within each of the four scenarios, the performance of a particular
estimator was assessed by examining the estimated bias and RMSE:
b̂ias(θ) =
1
10, 000
10,000∑
m=1
(
θˆ
(m)
S − θ(m)S
)
̂RMSE(θ) =
√√√√ 1
10, 000
10,000∑
m=1
(
θˆ
(m)
S − θ(m)S
)2
A different approach to calculating the bias and RMSE could be used where instead
of the true mean of the selected arm, θS , the largest true mean θ(1) could be used. That
approach was not implemented here because the purpose was not to estimate the largest
true mean. The purpose was to accurately estimate the true mean of the selected arm.
During the study design process, the selection method and timing should be set such that
the probability of selecting the arm with the largest true mean is optimal. Sponsors are
most interested in ensuring that the estimates obtained from such a study reflect the true
activity of the drug as it will be used in the general population.
Table 3.1 shows the probability of selecting the correct arm (i.e. the arm with θi = θ(1))
using the design parameters described above. When a study with a treatment-selection
design is conducted, t typically occurs fairly early in the study to take as much advantage
of the savings in patient numbers as possible. Given this, the table only reflects the range
of t values commonly used. Intuitively, the probability of selecting the correct arm was
generally better in studies with fewer arms to choose from, and this contrast was especially
apparent when there were smaller differences among the true means of the arms. In the
Linear Means scenario, studies with 3 arms had probabilities of selecting the correct arm
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Linear Means Two Active Arms One Active Arm
3 arms 5 arms 3 arms 5 arms 3 arms 5 arms
t=0.2 0.696 0.484 0.965 0.914 0.826 0.736
t=0.3 0.760 0.539 0.982 0.954 0.896 0.830
t=0.4 0.798 0.581 0.992 0.979 0.931 0.893
t=0.5 0.831 0.614 0.995 0.988 0.955 0.930
Table 3.1: Probabilities of selecting the correct arm in study designs with a normal end-
point.
between 70% and 83%, and they were approximately twenty percentage points lower in
studies with 5 arms. In the One Active Arm scenario, the probability was between 83%
and 96% for 3 arms and about 3 to 10 percentage points lower with 5 arms. With two
active arms, the probability of selecting the correct arm was consistently high (> 90%) for
both three-arm and five-arm studies.
3.2 Binomial Endpoints
For treatment-selection studies with binary endpoints, let Xi ∼ B(n1, θi) be the random
variable representing the number of responses observed in n1 patients enrolled to treatment
arm Ti. After the interim analysis, unless otherwise stated, the arm with the largest number
of responses (XS) was selected to continue to stage 2. If there were ties among multiple
arms, then the arm with the smaller index was selected (e.g. arm 1 was selected over arm
2). This was done to simulate the situation where each higher index represented a higher
dose. If ties arose in a study, sponsors may often choose to move forward with a lower dose
that has a potentially better safety profile. Let Yi ∼ B(n2, θS) be the random variable
representing the number of responses in n2 patients observed in the selected treatment TS .
To evaluate the performance of various estimators, four scenarios similar to those as-
sessed with normal endpoints were investigated using designs with k = 2 through 5 arms.
For k = 3 and k = 5, these scenarios were:
• Scenario 1 (“Equal Means”): θ = (0.38, 0.38, 0.38) or (0.38, 0.38, 0.38, 0.38, 0.38)
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Linear Means Two Active Arms One Active Arm
3 arms 5 arms 3 arms 5 arms 3 arms 5 arms
t=0.2 0.648 0.425 0.959 0.866 0.771 0.676
t=0.3 0.704 0.488 0.982 0.954 0.876 0.790
t=0.4 0.756 0.524 0.990 0.971 0.914 0.870
t=0.5 0.806 0.563 0.995 0.986 0.948 0.917
Table 3.2: Probabilities of selecting the correct arm in study designs with a binomial
endpoint.
• Scenario 2 (“Linear Means”): θ = (0.2, 0.29, 0.38) or (0.2, 0.245, 0.29, 0.335, 0.38)
• Scenario 3 (“Two Active Arms”): θ = (0.2, 0.38, 0.38) or (0.2, 0.2, 0.2, 0.38, 0.38)
• Scenario 4 (“One Active Arm”): θ = (0.2, 0.2, 0.38) or (0.2, 0.2, 0.2, 0.2, 0.38)
As with the simulations with normally distributed endpoints, t = n1n1+n2 ranged from 0.1
to 1.0, and a total of 10,000 simulations were generated for each value of t within each
scenario. With a total of n1 + n2 = 100 patients enrolled to the selected treatment arm
TS , there was 80% power to observe an increase in response rate from 0.20 to 0.38 between
two arms. The estimated bias and RMSE of each estimator were calculated as described
above.
The probability of selecting the correct arm in each scenario can be found in Table 3.2.
The probabilities were slightly lower than those observed with normally distributed end-
points. This was likely due to the discrete nature of the data coupled with the fact that
the arm with the lower index was selected in the case of ties, which led to the arms with
less activity being selected slightly more often. The same relative pattern as the normal
endpoints was observed in that the probability of selecting the correct arm was highest in
the Two Active Arms scenario and lowest in the Linear Means scenario, particularly with
a larger number of treatment arms.
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Chapter 4
Proposed Estimator 1: Parametric Bootstrap Resampling Estimator
4.1 Normal Endpoints
A treatment-selection design with k treatment arms was considered where the arm with
the largest mean was selected at the interim analysis (when n1 patients were enrolled to
each arm) and continued to stage 2. The observed mean based only on stage 2 data would
be an unbiased estimate of the true mean of the selected arm. The stage 1 mean, however,
would be biased due to the selection method, and would therefore require adjustment. If
there were no differences among the true treatment means of the arms, then the grand
mean of the data from all k arms, θˆ1S = X =
∑k
i=1Xi
k , would be the most accurate stage
1 estimate for the selected arm. It would also have very small variability since it would
be based on kn1 observations. Conversely, if there were large differences among the arms
with respect to their true means, then the maximum likelihood estimate of the selected
arm, θˆ1S = XS , would be the most reasonable choice.
When faced with stage 1 data from a treatment-selection study, one could ask ”Should
the grand mean be used as the stage 1 estimate?” To address this, one could conduct a
one-way analysis of variance, and if the differences among the treatment means were small
(e.g. ANOVA p > 0.05), then one could assume that the means were the same. In this
case, the data from all treatment arms could be reasonably pooled, and X would be a
reasonable option for θˆ1S . If the differences among the treatment means was large, then XS
may instead be used as the estimate. Having only two options for an estimator, however, is
sub-optimal for bias adjustment across the spectrum of possible true means. For instance,
if p = 0.051, the grand mean would be used as the estimator, but if the p-value was 0.049,
the MLE would be used. The differences between these two situations could be very subtle,
so a binary decision rule would not be optimal here. Greater flexibility would be preferable,
such as a linear combination of the observed means of the treatment arm, where the weights
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differ for each arm.
One could assign greater weight to the treatment arms that have higher probabilities of
being selected to stage 2 based on the observed stage 1 means, p(1)i. The linear combination
could then be calculated as:
θˆ1S =
k∑
i=1
p(1)iXi
If p(1)S approached 1, this would imply that the correct arm was selected with high prob-
ability, and θˆ1S would approach XS . If all p(1)i were approximately 1/k, this would suggest
that θ1 = θ2 = · · · = θS , and an estimate that was approximately equal to X would be
more appropriate. These p(1)i values can be calculated as:
p(1)i =
∞∫
−∞
Xi∫
−∞
· · ·
Xi∫
−∞
f(x1, ..., xk)dx1...dxi−1dxi+1...dxkdxi
Since the treatment arms were independent, f(x1, ..., xk) =
∏k
i=1 f(xi), and in this exam-
ple, f(xi) represented the probability density function of a N
(
θi, σ
2/n1
)
distribution.
As the θi values are generally unknown, the approach proposed here, and also described
in Pickard and Chang (2014), aimed to estimate p(1)i. Instead of using f(xi), the empiri-
cal distributions were instead used, employing the plug-in principle, where fˆ(xi) was the
probability density function of a N
(
Xi, σ
2/n1
)
distribution and fˆ(x1, ..., xk) =
∏k
i=1 fˆ(xi).
Estimates for p(1)i were then calculated as:
pˆ(1)i =
∞∫
−∞
Xi∫
−∞
· · ·
Xi∫
−∞
fˆ(x1, ..., xk)dx1...dxi−1dxi+1...dxkdxi
At this point, it was investigated whether a potential stage 1 estimate could be:
θˆ1S =
k∑
i=1
pˆ(1)iXi,
but this did not sufficiently reduce the bias, particularly in the Equal Means scenario. The
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pˆ(1)i values of each arm in a study were correlated with the observed treatment means (Xi),
so the arm with the largest Xi value always had the largest pˆ(1)i value. In the Equal Means
scenario, the differences among the Xi values were large enough such that the selected arm
often had an estimated selection probability that was fairly far from 1/k. As a result, the
selected arm was still assigned a relatively large weight in the above the linear combination,
so further refinement was needed.
In an effort to address this, the Euclidean distance, ν, was calculated between the vector(
pˆ(1)1, ..., pˆ(1)k
)
and the vector of expected p(1)i values when all θi were equal: (1/k, ..., 1/k).
To interpret this value ν, the distribution of Euclidean distances that arose when θ1 = θ2 =
· · · = θk was explored. This reference distribution was calculated using the following steps:
1. For each arm i, one value (X∗i ) was sampled from a N
(
0, σ2/n1
)
distribution to
represent the observed mean for the ith treatment arm
2. The value pˆ∗(1)i was calculated for each arm using X
∗
1 , ..., X
∗
k
3. ν∗ was calculated as the Euclidean distance between (pˆ∗(1)1, ..., pˆ
∗
(1)k) and (1/k, ..., 1/k)
4. Steps 1-3 were repeated 10,000 times to generate a reference distribution of ν∗ values.
The observed distance ν was then compared to this reference distribution to estimate the
probability that larger distances could be observed when all treatment arms were equal,
η = Pr(ν∗ > ν). Large values of η implied that there was a high probability that that all
θi were equal.
Using η and
(
pˆ(1)1, ..., pˆ(1)k
)
, the stage 1 parametric bootstrap (PB) estimate of θS was
calculated as:
θˆ1PB,S =
 ηX + (1− η)
∑k
i=1 pˆ(1)iXi if η ≤ ηc
X if η > ηc
The user-specified variable ηc ranged from 0 to 1 and controlled the stringency of the bias
reduction. Lower values of ηc led to X being used for θˆ
1
PB,S more frequently. Unless
otherwise specified, the results described here were generated using an ηc value of 1.
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The final point estimate, θˆPB,S , was then calculated using data from both stage 1 and
stage 2:
θˆPB,S = tθˆ
1
PB,S + (1− t)Y
As an example of this proposed approach, assume a study with a normally distributed
endpoint was conducted where stage 1 consisted of 40 patients in each of three arms. Let
(X1, X2, X3) = (0.15, 0.05, 0.50) with known σ
2 = 1. Using the empirical distributions
of the treatment arm means, the probability of each arm being selected for stage 2 was
estimated to be
(
pˆ(1)1, pˆ(1)2, pˆ(1)3
)
= (0.056, 0.018, 0.927). The Euclidean distance of this
vector from (1/3, 1/3, 1/3) was calculated as ν = 0.727. Comparing ν to the reference
distribution suggested that there was a probability of 0.0423 that these pˆ(1)i values (or
values more extreme) could be observed when all θi were equal, so η = 0.0423. With
ηc = 1, the stage 1 estimate was calculated as:
θˆ1PB,S = 0.9577 [(0.056)0.15 + (0.018)0.05 + (0.927)0.50] +
0.0423 [(0.33)0.15 + (0.33)0.05 + (0.33)0.50] = 0.46
T3 was then carried forward to stage 2, where an additional 60 patients were enrolled to
the treatment arm. If the observed stage 2 mean was 0.39, then the final estimate, θˆPB,S ,
was calculated as 0.40(0.46) + 0.60(0.39) = 0.42.
While evaluating θˆPB,S in the above-described simulation study, the computation time
required to perform the multiple integrations necessary to calculate each pˆ(1)i value was
large, so the integrations were replaced by parametric bootstrap resampling using the
empirical distributions from the simulated study of interest. Using these bootstrapped
samples, the proportion of the samples in which each arm was found to be the largest was
used for pˆ(1)i.
The approach described here was initially compared to the MLE, which did not take
into account the selection method. In this case, XS and Y were directly combined to
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estimate θS :
θˆMLE,S = tXS + (1− t)Y
A summary of the estimated bias and RMSE for k = 3 treatment arms is found in
Figure 4.1 and for k = 5 in Figure 4.2. θˆMLE,S resulted in an estimate that, on average,
over-estimated the true mean in the Equal Means, Linear Means, and Two Active Arms
scenarios. The bias of θˆMLE,S was more pronounced with larger k and when there were
smaller differences among the true means (e.g. the Equal Means scenario), which confirmed
the findings described by Bauer et al.. Given that the selected arm had a naive standard
error (SEM) of
√
σ2
n1+n2
= 0.1, the bias at t = 0.5 was approximately 60% of the SEM for
k = 3 and 82% of the SEM for k = 5 in the Equal Means scenario. The adjustments made
by using θˆPB,S resulted in reduced bias compared to θˆMLE,S in these same three scenarios.
Particularly in the Linear Means and Two Active Arms scenarios, the bias using θˆPB,S was
minimal. In the One Active Arm scenario, as t approached 1, θˆMLE,S was nearly unbiased
while θˆPB,S slightly underestimated the true mean. When t was in the range typically used
in this type of design (e.g. t between 0.2 and 0.5), θˆPB,S had similar or reduced bias with
respect to θˆMLE,S in all four scenarios.
The results in Figures 4.1 and 4.2 indicated that θˆPB,S still exhibited some bias in the
Equal Mean scenario (although less so than θˆMLE,S). In this scenario, η was uniformly
distributed between 0 and 1 (Figure 4.3), so on average, η was equal to 0.5. With ηc = 1,
this corresponded to an estimator where X and
∑k
i=1 p(1)iXi were equally weighted. There
was only a 10% chance that X would be assigned at least 90% of the weight in the Equal
Means scenario. This prevented θˆPB,S from exhibiting greater bias reduction in the Equal
Means scenario. One way to further reduce the bias was to change the value of ηc to be
less than 1. For any stage 1 data where η > ηc, the stage 1 estimate would be assigned
X. Figure 4.4 illustrates the impact of varying ηc from 1 to 0.2. The results revealed
an underlying complexity with estimation in treatment selection designs: improving the
estimator’s performance (i.e. bias and RMSE) in the Equal Means scenario resulted in
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Figure 4.1: Estimated bias (left column) and RMSE (right column) of θˆMLE,S and θˆPB,S
in study designs with 3 treatment arms and a normal endpoint with σ2 = 1 (largest stage
1 mean selected).
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Figure 4.2: Estimated bias (left column) and RMSE (right column) of θˆMLE,S and θˆPB,S
in study designs with 5 treatment arms and a normal endpoint with σ2 = 1 (largest stage
1 mean selected).
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Figure 4.3: Distribution of η values in study designs with 5 treatment arms and a normal
endpoint. Each plot shows the t = 0.2 (solid), t = 0.5 (dashed), and t = 0.8 (dotted). η
values close to 1 yielded estimates that approached X.
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Figure 4.4: Impact of decreasing ηc on bias and RMSE in study designs with 5 treatment
arms and a normal endpoint. Values of ηc were 1 (solid), 0.8 (short dashed), 0.6 (dotted),
0.4 (dashed and dotted), and 0.2 (long dashed)
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decreased performance in other scenarios.
Figure 4.3 illustrates the reason for this trade-off among the scenarios. There was
a large amount of overlap in the observed values of η across the various scenarios. For
instance, if ηc is set to 0.6 when t = 0.5, θˆ
1
PB,S was assigned the value of X 40% of the
time in the Equal Means scenario. In the Linear Means scenario, this probability was
13%. For both the Two Active Arms and One Active Arm scenarios, this probability was
between 3% and 5%. So while decreasing in ηc was beneficial in the Equal Means scenario, it
resulted in an underestimation in the Linear Means scenario. This was particularly striking
when ηc < 0.40, as even the One and Two Active Arms scenarios were largely impacted.
Similar reasoning explained why the bias was still overcorrected in the One Active Arm
scenario when ηc = 1, as X had some contribution to the adjusted stage 1 estimate in
many instances. It was also worth noting that some of the densities in Figure 4.3 had
plateaus (Linear Means) or were bimodal (Two Active Arms) when η was approximately
0.2. This seemed to arise under several conditions, particularly when multiple arms had
similarly large observed means, which occurred with high frequency in the Two Active
Arms scenario.
With respect to RMSE, θˆPB,S had similar or lower RMSE than θˆMLE,S in each scenario,
with the exception of the One Active Arm scenario. In order to investigate this, it was
recalled that the mean squared error was a function of both the variance and the squared
bias of the estimator:
MSE(θˆ) = E
[
(θˆ − θ)2
]
= E
[(
(θˆ − E[θˆ]) + (E[θˆ]− θ)
)2]
= E
[
(θˆ − E[θˆ])2
]
+ 2E
[
(θˆ − E[θˆ])
]
E
[
(E[θˆ]− θ)
]
+ E
[
(E[θˆ]− θ)2
]
= E
[
(θˆ − E[θˆ])2
]
+ E
[
(E[θˆ]− θ)2
]
= V ar(θˆ) + bias2(θ)
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Figure 4.5: Standard Error of θˆMLE,S and θˆPB,S for k = 3 (left) and k = 5 (right)
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Figure 4.6: Distribution of differences between θˆMLE,S and θˆPB,S in study designs with
5 treatment arms and a normal endpoint. Each plot shows t = 0.20 (solid), t = 0.50
(dashed), and t = 0.80 (dotted). Note that no differences were less than 0 (i.e. θˆPB,S
was never larger than θˆMLE,S). The small area of the One Active Arm plot that included
values less than zero was a result of the density estimation approach underestimating the
steepness of the curve at that point.
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Based on this, it was not unexpected that θˆPB,S had reduced RMSE compared to θˆMLE,S in
several scenarios, as it generally had less bias. It was not clear, however, how the variances
of the two estimates compared. Figure 4.5 shows the standard deviation of all simulated
θˆMLE,S and θˆPB,S values in each scenario for t = 0.2 and t = 0.5. This was interpreted
as the simulated estimate of the standard error for each estimator. The standard error of
θˆPB,S was larger than θˆMLE,S in all scenarios, suggesting that some of the decrease in the
θˆPB,S RMSE resulting from the reduced bias was offset to some degree by an increase in its
variability. This increase in standard error was a result of the variability in the amount by
which θˆPB,S was adjusted away from θˆMLE,S . If the difference between θˆPB,S and θˆMLE,S
was constant, the standard error of these two estimators would be the same. It can be seen
in Figure 4.6, however, that this difference varied from 0 to 0.14 when k = 5, depending
on the scenario and t. The variance of this difference increased with later selection times.
This occurred because in some instances, θˆPB,S and θˆMLE,S were very similar, while in
other instances, θˆPB,S was pulled fairly far from θˆMLE,S . This resulted in an added source
of variability and, therefore, the standard error of θˆPB,S increased. This explained why
the RMSE of the two estimators was similar despite reduced bias with θˆPB,S in the Linear
Means and Two Active Arms scenarios, and why θˆPB,S had higher RMSE in the One
Active Arm scenario.
It was also important to note that the variance of XS was not equal to the naive SEM,
σ2
n1
, in this type of design because the distribution of XS was not normally distributed. In
the Equal Means scenario (where all θi = 0.40), the distribution of XS was instead:
fXS (x) = kφ
(√
n1(x− 0.40)
σ
)[
Φ
(√
n1(x− 0.40)
σ
)]k−1
This non-normal distribution yielded a variance of XS that was smaller than
σ2
n1
. The
difference between the variance of XS and
σ2
n1
diminished in the scenarios where the true
mean of the selected arm was largely different from the rest.
To this point, only study designs where the largest mean was of interest have been
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assessed. In some settings, this may not be the optimal choice. For instance, higher doses
of a drug may improve efficacy, but it may come at the cost of increased toxicity. To provide
a better balance between safety and efficacy, identifying a lower (e.g. the second largest)
mean may be preferable. The estimator θˆPB,S can accommodate this situation, but there
were two possible ways to calculate it. The first of which was to use the same approach as
described above, but pˆ(j)i was calculated instead of pˆ(1)i, where j was the rank of interest.
Using the second approach, the arms with the observed means larger than the jth largest
were ignored, and the calculation of the reference distribution of Euclidean distances was
refined to reflect the fact that the larger arms were removed. This latter approach entailed:
1. For each arm i, one value (X∗i ) was sampled from a N
(
0, σ2/n1
)
distribution to
represent the observed mean for that treatment arm. Only instances where the same
arm had the largest mean were kept. For instance, any simulation where an arm
other than Arm 1 had the largest stage 1 mean was removed. This was done so that
the proportion of times each arm was selected was based on the same j arms. This
ensured the pˆ(j)i values were always calculated for the same arm.
2. The value pˆ∗(j)i was calculated for each arm using X
∗
(j), ..., X
∗
(k)
3. ν∗ was calculated as the Euclidean distance between (pˆ∗(j)j , ..., pˆ
∗
(j)k) and (1/j, ..., 1/j)
4. Steps 1-3 were repeated 10,000 times to generate a reference distribution of ν∗ values.
Figures 4.7 and 4.8 summarize the performance of these two approaches. The approach
where all arms remained in the analysis had very similar performance to θˆMLE,S . This
occurred because the value of pˆ(j)i was a non-zero value for the largest mean, and it
was often substantial in magnitude. As a result, the linear combination of the treatment
means,
∑k
i=1 p(1)iXi yielded a value for θˆ
1
PB,S that was pulled upwards towards X(1). This
essentially cancelled out much of the bias adjustment relative to θˆMLE,S . The second
approach of removing the arm with the largest stage 1 mean did result in a reduction
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in the estimate relative to θˆMLE,S , however, in some scenarios, the estimate was over-
corrected. With a small number of arms (e.g. k = 3), θˆMLE,S was nearly unbiased in
the Equal Means and Linear Means scenarios. In general, however, the bias of θˆPB,S was
similar or smaller than θˆMLE,S . This suggested that θˆ
1
PB,S could be used even when the
arm other than the largest is selected, particularly with larger k. It is recommended that
arms larger than the jth arm be removed and the study treated as one having j arms.
It is also important to keep in mind that neither θˆ1MLE,S nor θˆ
1
PB,S performed well in all
scenarios. Both perform particularly poorly in the Two Active Arms scenario.
4.2 Binomial Endpoint
A parametric bootstrap resampling approach could also be applied to studies with a binary
endpoint, and the calculation of θˆPB,S was similar to that of normal endpoints. The
probability of each arm being selected for stage 2, pˆ(1)i, was calculated using the empirical
distribution as described above, replacing integration with summation:
pˆ(1)i =
n1∑
Xi=1
Xi∑
X1=1
· · ·
Xi∑
Xi−1=1
Xi∑
Xi+1=1
· · ·
Xi∑
Xk=1
fˆ (x1, ..., xk)
where fˆ(x1, ..., xk) =
∏k
i=1 fˆ(xi) and fˆ(xi) ∼ B (n1, Xi/n1). The Euclidean distance, ν,
was calculated between (pˆ(1)1, ..., pˆ(1)k) and (1/k, ..., 1/k). The reference distribution of ν
was modified slightly since the variance of a binomial distribution was correlated with the
mean. So the steps taken were:
1. The value θ was calculated as (1/(kn1))
∑k
i=1Xi.
2. For each arm i, one value (X∗i ) was sampled from a B
(
n1, θ
)
distribution to represent
the observed responses for that treatment arm
3. The value pˆ∗(1)i was calculated for each arm using X
∗
1 , ..., X
∗
k
4. ν∗ was calculated as the Euclidean distance between (pˆ∗(1)1, ..., pˆ
∗
(1)k) and (1/k, ..., 1/k)
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Figure 4.7: Estimated bias (left column) and RMSE (right column) when estimating the
second largest stage 1 mean in study designs with 3 treatment arms and a normal endpoint
with σ2 = 1. Estimators: θˆMLE,S (solid) θˆPB,S after removing the arm with the largest
stage 1 mean (dashed), θˆPB,S when keeping all arms (dotted)
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Figure 4.8: Estimated bias (left column) and RMSE (right column) when estimating the
second largest stage 1 mean in study designs with 5 treatment arms and a normal endpoint
with σ2 = 1. Estimators: θˆMLE,S (solid) θˆPB,S after removing the arm with the largest
stage 1 mean (dashed), θˆPB,S when keeping all arms (dotted)
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5. Steps 2-4 were repeated 10,000 times to generate a reference distribution of ν∗ values.
Whenever there were ties in the number of responses among the arms, the arm with the
lower index was selected for stage 2 in order to be consistent with Tappin (1992). η was
then calculated as Pr(ν∗ > ν). The stage 1 estimate was calculated as:
θˆ1PB,S =

1
n1
∑k
i=1
[
(1− η)pˆ(1)i + η 1k
]
Xi if η ≤ ηc
1
kn1
∑k
i=1Xi if η > ηc
 ,
where ηc was the user-defined variable described in the previous section. The final estimate
was then calculated as:
θˆPB,S = tθˆ
1
PB,S + (1− t)
Y
n2
A comparison of this estimator with others is found later in this dissertation.
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Chapter 5
Proposed Estimator 2: Empirical Bayes Estimator
5.1 Normal Endpoint
As an alternative to the parametric bootstrap resampling approach, estimation in treatment-
selection designs could also be conducted in a Bayesian context. Let G1, ..., Gk be the
observed means of k groups, each with N(θi,
σ2
Ni
) distribution, with σ2 known and θi ∼
N(µ, τ2). Note that Gi is based on a different number of patients, Ni. One could use the
posterior expectation of θi, the true mean of arm i, as an estimate instead of using Gi. If
a largely non-informative normal prior was used (i.e. τ2 large), the posterior expectation
of arm i would be similar to Gi. Conversely, if a highly informative prior was used (i.e.
τ2 small), the posterior estimate would be pushed towards the prior mean µ. In order to
avoid specifying a single prior distribution before the study began, the observed data could
instead determine the parameters of the prior distribution using an empirical Bayesian
approach.
As previously discussed, James and Stein (1961) defined a shrinkage estimator that
“shrank” the MLE towards the origin. In the setting described above, the James-Stein
estimator would be:
θˆJS,i =
(
1− (k − 2)σ
2
Ni||G||2
)
Gi
where ||G||2 = ∑ki=1G2i . Since empirical Bayes estimators had the same attractive prop-
erties of shrinkage estimators, namely lower MSE across all groups (i.e. ensemble MSE),
they could be a potentially useful estimator in the context of treatment-selection designs.
In order to identify an empirical Bayes estimator, the marginal distribution of the
observed data given the hyperparameters µ and τ2 was required. This would lead to
the identification of data-driven estimates for µ and τ2. Let G1 represent the observed
mean from a single arm, where f(G1|θ1) ∼ N(θ1, σ2N1 ), σ2 known, and prior distribution
pi(θ1|µ, τ2) ∼ N(µ, τ2). The distribution of (G1, θ1|µ, τ2) was found to be:
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f(g1, θ1|µ, τ2) = pi(θ1|µ, τ2)f(G1|θ1)
=
1√
2piτ2
exp
{
−(θ1 − µ)
2
2τ2
}[
1√
2piσ2/N1
exp
{
−(G1 − θ1)
2
2σ2/N1
}]
=
(
1
2pi
)√
N1
τ2σ2
exp
{
−1
2
[
(θ1 − µ)2
τ2
+
N1 (G1 − θ1)2
σ2
]}
The exponential term could be rearranged:
(θ1 − µ)2
τ2
+
N1 (G1 − θ1)2
σ2
=
θ21 − 2θ1µ+ µ2
τ2
+
N1G
2
1 − 2N1θ1G1 +N1θ21
σ2
=
(
1
τ2
+
N1
σ2
)
θ21 − 2
(
N1G1
σ2
+
µ
τ2
)
θ1 +
N1G
2
1
σ2
+
µ2
τ2
=
(
1
τ2
+
N1
σ2
)[
θ21 − 2
(
N1G1
σ2
+ µ
τ2
1
τ2
+ N1
σ2
)
θ1
]
+
N1G
2
1
σ2
+
µ2
τ2
=
(
1
τ2
+
N1
σ2
)[
θ21 − 2
(
N1G1
σ2
+ µ
τ2
1
τ2
+ N1
σ2
)
θ1 +
(
N1G1
σ2
+ µ
τ2
)2(
1
τ2
+ N1
σ2
)2
]
−
(
N1G1
σ2
+ µ
τ2
)2
1
τ2
+ N1
σ2
+
N1G
2
1
σ2
+
µ2
τ2
=
(
1
τ2
+
N1
σ2
)[
θ1 −
N1G1
σ2
+ µ
τ2
1
τ2
+ N1
σ2
]2
−
(
N1G1
σ2
+ µ
τ2
)2
1
τ2
+ N1
σ2
+
N1G
2
1
σ2
+
µ2
τ2
Note that:
N1
σ2
+
1
τ2
=
σ2τ2
σ2τ2
(
1
τ2
+
N1
σ2
)
=
N1τ
2 + σ2
σ2τ2
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Continuing to rearrange the exponential term:
(θ1 − µ)2
τ2
+
N1 (G1 − θ1)2
σ2
=
(
1
τ2
+
N1
σ2
)[
θ1 −
N1Gi
σ2
+ µ
τ2
1
τ2
+ N1
σ2
]2
+
N1G2i
σ2
(
N1τ2+σ2
σ2τ2
)
N1τ2+σ2
σ2τ2
−
(
N1G1
σ2
+ µ
τ2
)2
N1τ2+σ2
σ2τ2
+
µ2
τ2
(
N1τ2+σ2
σ2τ2
)
N1τ2+σ2
σ2τ2
=
(
1
τ2
+
N1
σ2
)[
θ1 −
N1G1
σ2
+ µ
τ2
1
τ2
+ N1
σ2
]2
+
N21 τ
2G21
σ4τ2
+
N1G21
σ2τ2
− N21G21
σ4
− 2µN1G1
σ2τ2
− µ2
τ4
+ N1µ
2
σ2τ2
+ µ
2
τ4
N1τ2+σ2
σ2τ2
=
(
1
τ2
+
N1
σ2
)[
θ1 −
N1G1
σ2
+ µ
τ2
1
τ2
+ N1
σ2
]2
+
N21 τ
2G21−τ2N21G21
σ4τ2
+
N1G21−2µN1G1+N1µ2
σ2τ2
N1τ2+σ2
σ2τ2
=
(
1
τ2
+
N1
σ2
)[
θ1 −
N1G1
σ2
+ µ
τ2
1
τ2
+ N1
σ2
]2
+
N1(G1−µ)2
σ2τ2
N1τ2+σ2
σ2τ2
=
(
1
τ2
+
N1
σ2
)[
θ1 −
N1G1
σ2
+ µ
τ2
1
τ2
+ N1
σ2
]2
+
N1 (G1 − µ)2
N1τ2 + σ2
Inserting this rearranged exponential term back into the original equation led to:
f(g1, θ1|µ, τ2) =
(
1
2pi
)√
N1
τ2σ2
∗
exp
−12
(
1
τ2
+
N1
σ2
)[
θ1 −
N1G1
σ2
+ µ
τ2
1
τ2
+ N1
σ2
]2 exp
{
− N1 (G1 − µ)
2
2 (N1τ2 + σ2)
}
As this was the distribution when there was only one arm, it needed to be expanded for
multiple arms to be applicable in a treatment-selection design. In this setting, GS = θˆMLE,S
and the rest of the Gi, i 6= S, were equivalent to Xi. As these arms were independent, the
joint distribution using this type of design would be the product of each arm’s individual
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distribution
∏k
i=1 f(gi, θi|µ, τ2). Assuming the same µ and τ2 parameters for all arms:
f(g1, g2, ..., gk, θ1, ..., θk|µ, τ2) =
(
1
2pi
)k ( 1√
τ2
)k k∏
i=1
(√
Ni
σ2
)
exp
−12
k∑
i=1
(
1
τ2
+
Ni
σ2
)
∗
[
θi −
NiGi
σ2
+ µ
τ2
1
τ2
+ Ni
σ2
]2 exp
{
k∑
i=1
− Ni (Gi − µ)
2
2 (Niτ2 + σ2)
}
All θi were then integrated out to obtain the marginal distribution:
m(g1, ..., gk|µ, τ2) =
∫
· · ·
∫
f(g1, ..., gk, θ1, ..., θk|µ, τ2)dθ1...dθk
=
(
1
2pi
)k ( 1√
τ2
)k k∏
i=1
(√
Ni
σ2
)
exp
{
k∑
i=1
− Ni (Gi − µ)
2
2 (Niτ2 + σ2)
}
∗
∫
· · ·
∫
exp
−12
k∑
i=1
(
1
τ2
+
Ni
σ2
)[
θi −
NiGi
σ2
+ µ
τ2
1
τ2
+ Ni
σ2
]2 dθ1...dθk
=
(
1
2pi
)k ( 1√
τ2
)k k∏
i=1
(√
Ni
σ2
)
exp
{
k∑
i=1
− Ni (Gi − µ)
2
2 (Niτ2 + σ2)
}
∗
k∏
i=1
(√
2pi
1
τ2
+ Ni
σ2
)
=
(
1√
2piτ2
)k k∏
i=1
[(√
1
Niτ2+σ2
σ2τ2
)(√
Ni
σ2
)]
∗
exp
{
k∑
i=1
− Ni (Gi − µ)
2
2 (Niτ2 + σ2)
}
=
(
1√
2piτ2
)k k∏
i=1
√ Niτ2
Niτ2 + σ2
 exp{ k∑
i=1
− Ni (Gi − µ)
2
2 (Niτ2 + σ2)
}
=
(
1√
2pi
)k k∏
i=1
(√
Ni
Niτ2 + σ2
)
exp
{
k∑
i=1
− Ni (Gi − µ)
2
2 (Niτ2 + σ2)
}
m(g1, ..., gk|µ, τ2) =
k∏
i=1
(
1√
2pi
)(√
Ni
Niτ2 + σ2
)
exp
{
− Ni (Gi − µ)
2
2 (Niτ2 + σ2)
}
It could be seen that the marginal distribution, m(g1, ..., gk|µ, τ2), was a multivariate nor-
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mal distribution with µ = (µ, ..., µ) and
Σ =

τ2 + σ2/N1 0 · · · 0
0 τ2 + σ2/N2 · · · 0
...
...
. . .
...
0 0 · · · τ2 + σ2/Nk

The log-likelihood was then identified as:
log(m(g1, ..., gk|µ, τ2)) =
−k
2
log (2pi) +
1
2
k∑
i=1
log(Ni)− 1
2
k∑
i=1
log
(
σ2 +Niτ
2
)− k∑
i=1
Ni (Gi − µ)2
2(Niτ2 + σ2)
Estimates of µ and τ2 that maximized this function could then be identified. The MLE of
µ was found by solving:
d
dµ
log(m(g1, ..., gk|µ, τ2)) = 0
d
dµ
− k∑
i=1
(Gi − µ)2
2
(
τ2 + σ
2
Ni
)
 = 0
=
k∑
i=1
(Gi − µ)
τ2 + σ
2
Ni
= 0
This yielded the solution:
µˆ =
∑k
i=1
[∏k
j=1;j 6=i
(
τˆ2 + σ
2
Nj
)
Gi
]
∑k
i=1
[∏k
j=1;j 6=i
(
τˆ2 + σ
2
Nj
)]
Since the arms that stopped in stage 1 had the same Ni = n1, this was simplified to:
µˆ =
∑k
i=1wiGi∑k
i=1wi
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where:
wi =
 τˆ
2 + σ
2
n1
if i = S
τˆ2 + σ
2
n1+n2
if i 6= S
The MLE for τ2 was the solution to:
d
dτ2
log(m(g1, ..., gk, N1, ..., Nk, µ, τ
2))
d
dτ2
(
−1
2
k∑
i=1
log
(
σ2 +Niτ
2
)− k∑
i=1
Ni (Gi − µ)2
2(Niτ2 + σ2)
)
=
k∑
i=1
N2i (Gi − µˆ)2
2 (σ2 +Niτ2)
2 −
k∑
i=1
Ni
2 (σ2 +Niτ2)
= 0
=
k∑
i=1
(Gi − µˆ)2(
σ2
Ni
+ τ2
)2 − k∑
i=1
1(
σ2
Ni
+ τ2
) = 0
With equal Ni per arm, the estimators for µ and τ
2 would have been:
µˆ =
∑k
i=1Gi
k
and τˆ2 = max
(∑k
i=1(Gi − µˆ)2
k
− σ
2
Ni
, 0
)
With treatment-selection designs, the different Ni values prevented the estimation of µ and
τ2 from having a closed-form solution. It could be seen that the estimate for the mean
of the prior distribution, µˆ, was dependent upon the estimate of the variance, τˆ2. When
large differences existed in the observed means, τˆ2 was large (non-informative prior), and
µˆ converged towards a mean of G1, ..., Gk where each arm was weighted equally. This was
the same estimator used when the number of patients was the same in each arm. When
small differences existed in the observed means, then τˆ2 was small (informative prior), and
µˆ was a weighted average of the arms, with the arm moving on to stage 2 having the largest
weight.
Using the prior distribution with estimated parameters µˆ and τˆ2, an adjusted estimate
of the mean for the selected arm was generated by calculating the posterior expectation of
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Figure 5.1: Estimated bias and RMSE using θˆMLE,S and θˆEB,S in study designs with 3
treatment arms and a normal endpoint (largest stage 1 mean selected).
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Figure 5.2: Estimated bias and RMSE using θˆMLE,S and θˆEB,S in study designs with 5
treatment arms and a normal endpoint (largest stage 1 mean selected).
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θS :
θˆEB,S =
σ2
(n1 + n2)τˆ2 + σ2
µˆ+
(n1 + n2)τˆ
2
(n1 + n2)τˆ2 + σ2
θˆMLE,S
To identify µˆ and τˆ2, µˆ was calculated for values of τˆ2 ranging from 0 to 3 by increments of
0.001. The combination of µˆ and τˆ2 values that yielded the largest log likelihood was used
as the final estimates. Using θˆEB,S , the bias and RMSE for the four previously described
scenarios in a study with three arms are shown in Figure 5.1. Similar results were observed
with five arms, as shown in Figure 5.2. In both cases, θˆEB,S reduced the bias very well
relative to θˆMLE,S in the Equal Means scenario, with θˆEB,S being nearly unbiased. This
occurred because τˆ2 was found to be nearly 0 in many instances (i.e. a highly informative
prior distribution). When k = 5 in the Equal Means scenario, the value of τˆ2 was estimated
to be 0 a total of 81% and 73% of the time when t = 0.2 and t = 0.5, respectively. Since
the prior distribution was a single point estimate in these instances, θˆEB,S = µˆ. In the One
Active Arm scenario, the value of τ2 was estimated to be 0 only 28% and 7% of the time
when t = 0.2 and t = 0.5, respectively. These results indicated that the empirical Bayes
approach was able to account for the differences among the observed means by increasing
the variance of the prior distribution.
The estimate of θS was over-corrected, however, using θˆEB,S in the One Active Arm
scenario. This occurred because τˆ2 was not sufficiently large. As an example of this, let
θˆMLE,S = 0.39 and the observed stage 1 means in the other arms be denoted as X
C =
{0.05, 0.11, 0.04, 0.05}. Using the empirical Bayes approach, the parameters for the prior
distribution were determined to be µˆ = 0.15 and τˆ2 = 0.01, so θˆEB,S = 0.27. In order for
θˆMLE,S− θˆEB,S = 0.01, the prior distribution would need to have parameters µˆ = 0.13 and
τˆ2 = 0.25.
These results were not unusual for shrinkage estimators. Because the τˆ2 was not suffi-
ciently large, θˆEB,S generally underestimated the true mean when a small number of arms
had true means that were quite different from the rest. Even though these estimators have
similar or reduced ensemble MSE compared to the MLE (depending on the number of
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arms), they do not always have reduced MSE for individual arms (i.e. component MSE).
This is particularly true when an arm has a true mean that is very different from the prior
mean. In reality, the prior in this case should be a mixture of distributions, each hav-
ing different µi, where the differences among the µi were large. Efron and Morris (1972)
recognized this shortcoming and proposed a “limited translation” estimator whereby the
estimate of a group could not be further than a specified distance from θˆMLE,i. Assuming
a prior mean of 0 for all groups, they proposed that this limited translation only be used
when
∣∣∣ AA+1Gi −Gi∣∣∣ ≥ δ√A+1 , where A = Niτ2/σ2 and (A/(A + 1))Gi was the empirical
Bayes estimator. The value of δ determined the risk of the estimator, which struck a
balance between the ensemble MSE and the component MSE.
Given the limitation of shrinkage estimators (i.e. the over-correction for bias when only
one treatment arm is different from the rest), it seemed that an approach similar to that
proposed by Efron and Morris could improve upon the estimation. To use this approach,
the situation where it should be implemented needed to be defined, as well as the value
of δ to be used. A logical first step to identifying when limited translation should be
implemented was to examine the F-statistic summarizing the differences across all arms:
F =
∑k
i=1Ni(Gi −G)2/(k − 1)∑k
i=1
∑Ni
j=1(gij −Gi)2/
(∑k
i=1Ni − k
)
where gij was the j
th patient’s observation in the ith arm, G was the average of all ob-
servations across all treatment arms, and Ni = n1 + n2 when i = S and n1 otherwise.
Casella (1985) discussed that, when using an empirical Bayes estimator, the amount of
shrinkage towards µˆ was directly related to F . Figure 5.3 shows the relationship between
the log of the F-statistic and the log of the standardized difference between the MLE and
the empirical Bayes estimate:
D =
√
n1 + n2
(
|θˆMLE,S − θˆEB,S |
)
σ
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As previously discussed, XS , and therefore θˆMLE,S , was not necessarily normally dis-
tributed, with both the distribution and the variance dependent upon the true means.
This made accurate estimation of the variance of |θˆMLE,S− θˆEB,S | infeasible. This was the
reason that |θˆMLE,S − θˆEB,S | was instead normalized by σ2n1+n2 .
For small F-statistic values, D increased with F until it reached a maximum, at which
point D then began to decrease with higher F values. Based on the fact that θˆEB,S was
nearly unbiased in the Equal Means scenario, it appeared that D was appropriate for small
F values (i.e. no differences among arms). In the One Active Arm scenario, the estimate
over-corrected for the bias, so D was too large for some instances where F was large. Since
large F-statistics could occur in many scenarios (e.g. Linear Means, Two Active Arms, One
Active Arm), additional information was needed to isolate the case where only one arm
was largely different from the rest. To address this, the standardized difference between
θˆMLE,S and the second largest mean in stage 1, X(2), was calculated:
ω =
θˆMLE,S −X(2)√
σ2
n1+n2
+ σ
2
n1
Much like D, the variance of ω could not be calculated exactly as it depended on the values
of θ and t. In the Equal Means scenario and t = 0.50, there would be a small correlation
of about 0.30 between θˆMLE,S and X(2), but this would decrease with smaller t, and it
would approach 0 in the One Active Arm scenario. The choice of the variance estimate
used to normalize θˆMLE,S −X(2), however, did not have an impact on the performance of
the estimator.
Both ω and F were then used in combination to improve the empirical Bayes estimator.
The ω values were examined in the Equal Means scenario, and the 90th percentile, ω(c,0.90),
was deemed to be an appropriate cut-off. The log(D) versus log(F ) relationship was then
re-examined for only the observations where there were large differences between θˆMLE,S
and X(2), defined as ω > ω(c,0.90). This relationship was better defined, as shown in Fig 5.4,
and it could be modeled using either linear or piecewise linear regression models.
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Figure 5.3: log(D) versus log(F ) in study designs with a normal endpoint. For all four
plots, t = 0.5.
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Figure 5.4: log(D) vs log(F ) in study designs with a normal endpoint and ω >
ω(c,0.90)(t=0.5)
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Based on the performance of θˆEB,S , it was clear that D was too large for large values
of F . To address this, D was constrained to not exceed some specified distance, δ, from
θˆMLE,S . The limited translation function was defined such that large values of F forced
estimates to be closer to θˆMLE,S , thus reducing the bias. To increase the likelihood that
it was only used in the One Active Arm scenario, this limited translation only occurred
when both F and ω were large.
Identifying the critical value of F , beyond which limited translation would be used,
required a balance between a value that could adjust the majority of estimates in the
One Active Arm scenario and leave the majority of estimates in the Equal Means scenario
unadjusted. A reasonable balance was found when limited translation was implemented
when F > F0.85,df1,df2 where df1 = k − 1 and df2 =
∑k
i=1Ni − k and when ω > ω(c,0.90).
This limited translation function then decreased linearly such that it passed through the
point D = 0.01 when F = F0.99,df1,df2. To fully define the function, the changes in the slope
and intercept of the linear relationship between log(D) and log(F ) needed to be examined
under different conditions. Doing so allowed for the value of D when F = F0.85,df1,df2 to
be predicted.
The first step was to calculate ω(c,0.90) for a number of scenarios. Various values of
k, t,NS , and σ
2 were examined leading to 19 combinations of k = (2, 3, 4, 5, 6), NS = n1 +
n2 = (100, 200, 300), and σ = (0.1, 0.8, 1, 1.2, 10). Each combination was then evaluated
separately for values of t = (0.30, 0.40, 0.50, 0.60, 0.70). For each combination of k,NS , σ,
and t, all θi were set to 0 and 1000 simulated treatment-selection studies were conducted.
For each simulated study, the value ω was calculated. The value ω(c,0.90) was then identified
for each combination of k,NS , σ, and t as the 90
th percentile of the respective distribution.
Having defined ω(c,0.90), an additional 1000 simulations were conducted using the same
values of k,NS , σ, and t as described above. In this case, θ = (0, ..., 0, θS) where θS was a
value that had between 60% and 90% power to be detected compared to an arm with a
true mean of 0. For each set of 1000 simulations, the observations where ω > ω(c,0.90) were
identified and the relationship between log(D) and log(F ) was examined. As shown in
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Figure 5.4, this relationship was not always entirely linear, so a piecewise linear regression
model was fit to identify the breakpoint, and then the intercept and slope of the right
portion of the model (i.e. large F values) were estimated. Using the estimated intercept and
slope, the predicted value of log(D) when log(F ) = log(F0.85,df1,df2) was determined. These
predicted values of log(D), log(Dˆ0.85,df1,df2), were then modeled using forward selection to
identify the best fitting model among the various factors. The final model was selected
after ensuring model stability:
log(Dˆ0.85,df1,df2) = −0.52 + 0.042k + 0.32t+ 0.0017
k∑
i=1
Ni − 0.0016NS+
0.11kt− 0.00013k
k∑
i=1
Ni − 0.00086t
k∑
i=1
Ni
With the value of D at F0.85,df1,df2 estimated, the limited translation function was then
defined when ω > ω(c,0.90). Let DLT be the targeted standardized distance between a
limited translation estimate, θˆLT,S , and θˆMLE,S . Then:
log(DLT ) = β0 + β1log(F )
DLT = e
β0F β1
where:
β1 =
log(0.01)− log(Dˆ0.85,df1,df2)
log(F0.99,df1,df2)− log(F0.85,df1,df2)
β0 = log(0.01)− β1log(F0.99,df1,df2)
The limited translation (LT) estimator was then defined as:
θˆLT,S = (1−B)θˆMLE,S +Bµˆ
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Figure 5.5: Graphical representation of limited translation function. Points represent
simulated values in the One Active Arm scenario with k = 5, t = 0.5, and ω > ω(c,0.90).
The solid line is the linear regression of these points, and the dashed line is the limited
translation function that goes from the point (log(F0.85,df1,df2), log(Dˆ0.85,df1,df2)) through
the point (log(F0.99,df1,df2), log(0.01)).
where:
B =

δ
|θˆMLE,S−µˆ| if ω > ω(c,0.90) and F > F0.85,df1,df2
σ2
(n1+n2)τˆ2+σ2
otherwise
where δ =
√
σ2
n1+n2
DLT . Figure 5.5 illustrates the limited translation function graphically.
Using this proposed method, θˆLT,S very quickly approached θˆMLE,S when ω > ω(c,0.90) and
F > F0.85,df1,df2. Otherwise, θˆEB,S was used.
The performance of θˆLT,S was compared to both the MLE and the empirical Bayes
approach as shown in Figures 5.6 and 5.7. The LT estimator had reduced bias compared
to the empirical Bayes estimator when there were differences among the treatment arms.
This came at the expense of a slight (but near negligible) increase in the bias when the
treatment arms were all equal. Much like θˆPB,S , both θˆLT,S and θˆEB,S showed a marked
decrease in RMSE compared to θˆMLE,S in the Equal Means scenario. This was largely due
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to the fact that when τˆ2 was estimated to be 0, the variance of θˆEB,S was equal to V ar(µˆ):
V ar(θˆEB,S) = V ar
(
σ2
n1+n2
τˆ2 + σ
2
n1+n2
µˆ+
τˆ2
τˆ2 + σ
2
n1+n2
θˆMLE,S
)
= V ar(µˆ)
= V ar
(∑k
i=1wiGi∑k
i=1wi
)
.
Since µˆ was calculated based on all of the observed data, this led to a smaller variance
than θˆMLE,S . For θˆLT,S , there was a slight increase in the RMSE due to the increase in
variance compared to θˆEB,S resulting from the small number of simulated studies where
the estimate was shifted towards θˆMLE,S as a result of limited translation. For k = 3 and
t = 0.5, this shift occurred only 6% of the time, and for k = 5, it occurred only 4% of the
time.
For the One Active Arm scenario, an increase in the RMSE was observed for θˆEB,S
and θˆLT,S . With θˆLT,S , the limited translation allowed for the estimator to have similar
variance to θˆMLE,S , which was smaller than the variance of θˆEB,S . However, the empirical
Bayes estimate was still used (i.e. no limited translation) 25% of the time at t = 0.5
for both k = 3 and k = 5. This resulted in a bimodal distribution for θˆLT,S , as some
simulated studies were shrunk towards µˆ, while others are pulled towards θˆMLE,S . This
caused the variance to remain higher compared to θˆMLE,S . The decrease in the RMSE of
θˆLT,S compared to θˆEB,S was due primarily to the decrease in bias.
The performance of θˆLT,S was also evaluated in the situation where the 2
nd largest
stage 1 mean was of interest, as shown in Figure 5.8 and 5.9 for k = 3 and k = 5. In this
case, the arm with the largest mean was removed prior to the estimation. Much like θˆPB,S ,
the performance of θˆLT,S in this setting was mixed, depending on the number of arms and
the true means.
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Figure 5.6: Estimated bias and RMSE of θˆMLE,S , θˆEB,S , and θˆLT,S in a study design with
3 treatment arms and a normal endpoint (largest stage 1 mean selected)
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Figure 5.7: Estimated bias and RMSE of θˆMLE,S , θˆEB,S , and θˆLT,S in a study design with
5 treatment arms and a normal endpoint (largest stage 1 mean selected).
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Figure 5.8: Estimated bias and RMSE of θˆMLE,S and θˆLT,S in a study design with 3
treatment arms and a normal endpoint (second largest stage 1 mean selected)
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Figure 5.9: Estimated bias and RMSE of θˆMLE,S and θˆLT,S in a study design with 5
treatment arms and a normal endpoint (second largest stage 1 mean selected)
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5.2 Binomial Endpoint
An empirical Bayes approach was also implemented for binary endpoints. Let G1, ..., Gk
be the total observed responses for each arm, where Gi = XS + Y for the arm selected to
continue to stage 2, and Gi = Xi otherwise. Since each Gi was distributed as B(Ni, θi),
where Ni = n1 +n2 for i = S and n1 otherwise, the conjugate prior for θi was a Beta(α, β)
distribution. With an empirical Bayes approach, the observed responses could then dictate
the values used for the prior parameters α and β.
Starting with k = 1, the joint distribution of (G1, θ1|N1, α, β) was:
f(g1, θ1|N1, α, β) = pi(θ1|α, β)f(g1|Ni, θ1)
=
Γ(α+ β)
Γ(α)Γ(β)
θα−11 (1− θ1)β−1
(
N1
g1
)
θg11 (1− θ1)N1−g1
=
Γ(α+ β)
Γ(α)Γ(β)
(
N1
g1
)
θg1+α−1i (1− θ1)N1−g1+β−1
As previously discussed, the arms in a treatment-selection design were independent,
so the joint distribution in a study with multiple arms was the product of each arm’s
individual joint distribution
∏k
i=1 f(gi, θi|Ni, α, β). It was assumed that the same α and β
parameters were used for all arms, so:
f(g1, g2, ..., gk, θ1, ..., θk|N1, ..., Nk, α, β) =
(
Γ(α+ β)
Γ(α)Γ(β)
)k k∏
i=1
(
Ni
gi
)
θgi+α−1i (1− θi)Ni−gi+β−1
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All θi were then integrated out to obtain the marginal distribution:
m(g1, ..., gk|N1, ..., Nk, α, β) =
∫
· · ·
∫
f(g1, ..., gk, θ1, ..., θk|N1, ..., Nk, α, β)dθ1...dθk
=
(
Γ(α+ β)
Γ(α)Γ(β)
)k k∏
i=1
(
Ni
gi
)
∗
∫
· · ·
∫ k∏
i=1
θgi+α−1i (1− θi)Ni−gi+β−1dθ1...dθk
=
k∏
i=1
(
Ni
gi
)
Γ(α+ β)
Γ(α)Γ(β)
Γ(gi + α)Γ(Ni − gi + β)
Γ(Ni + α+ β)
=
k∏
i=1
Γ(Ni + 1)
Γ(gi + 1)Γ(Ni − gi + 1)
Γ(α+ β)
Γ(α)Γ(β)
∗
Γ(gi + α)Γ(Ni − gi + β)
Γ(Ni + α+ β)
The marginal distribution was therefore the product of k beta-binomial distributions, with
each having parameters Ni, Gi, α, and β.
Maximizing this likelihood was more complicated than with the normally distributed
endpoint. To identify the estimates for the prior parameters, αˆ and βˆ, simulated annealing
was used following the process outlined in Bertsimas and Tsitsiklis (1993). Each time the
algorithm was run, α and β were both assigned starting values of 1. Each Markov chain
had a length of 10,000, and for each state of α and β, the log likelihood was calculated.
The acceptance probability for the proposed state was calculated using the Metropolis
algorithm:
A(u) = min
(
exp
{
llnew − llcurr
T (u)
}
, 1
)
where llnew was the log likelihood value (i.e. log(m(g1, ..., gk|N1, ..., Nk, α, β))) of the new
proposed state and llcurr was the log likelihood value of the current state. The cooling
schedule (T (u)) used was:
T (u) =
20
log(u)
where u was the length of the chain. A uniform random variable was used to determine
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whether the proposed state replaced the current state.
Once the Markov chain had reached its maximum length, the final values for αˆ and
βˆ were then identified as those that yielded the largest log likelihood across the entire
chain. To prevent αˆ and βˆ from spanning several orders of magnitude across simulations,
the constraint αˆ + βˆ ≤ 5NS was applied. The empirical Bayes estimate could then be
calculated as the expectation of the posterior distribution for θS :
θˆEB,S =
αˆ+GS
αˆ+ βˆ + n1 + n2
To ensure that the estimate had reasonable performance in the One Active Arm sce-
nario, limited translation was once again implemented. Rather than using the F-statistic
calculated across all arms, the value of F was set to the statistic from a χ2 test across
all arms. The value log(F ) was then compared to log(D) where D was the χ2 statis-
tic comparing the difference between θˆMLE,S and θˆEB,S . To be consistent with the nor-
mally distributed endpoints, the point at which limited translation began was set to be
F = χ20.85,k−1. To identify the predicted value of log(D) at this point, the changes in
the slope and intercept of the linear relationship between log(D) and log(F ) were ex-
amined across various values of k, t, and Ni. θS was set to be a value that had be-
tween 78% and 98% power to be detected relative to proportions ranging from 0.2 to
0.5 (e.g. θ = (0.2, 0.2, ..., 0.2, θS)) or (0.5, 0.5, ..., 0.5, θS)). This led to 36 combinations of
k = (2, 3, 4, 5, 6), n1 + n2 = (100, 200, 300), and θ. Each combination was then evaluated
by performing 500 simulations at each value of t = (0.30, 0.40, 0.50, 0.60, 0.70).
The difference between θˆMLE,S and X(2) was also calculated using the χ
2 statistic, and
this was assigned to the value ω. In a departure from the approach used with normal
endpoints, ω(c,0.90) was determined for each simulated trial. To calculate this, each of the
θi values was set to θ =
∑k
i=1G
∗
i /
∑k
i=1N
∗
i . After completion of all simulations, the log(D)
versus log(F ) relationship was then examined for only the observations where there were
large differences between θˆMLE,S and X(2), defined as ω > ω(c,0.90). This relationship is
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shown in Figure 5.10, and it can be seen that this relationship was fairly linear.
For each combination of k,NS , t, and θ, linear regression was used to model the log(D)
vs log(F ) relationship. The intercepts and slopes of each model were used to calculate
the predicted value of log(D) when log(F ) = log(χ20.85,k−1). These predicted values,
log(Dˆ0.85,k−1) were then modeled using forward selection to identify the best fitting model
of the various factors. The final model was selected after ensuring model stability:
log(Dˆ0.85,k−1) = −5.271 + 0.475k + 3.609t− 0.00368NS
The empirical Bayes estimator was utilized whenever ω < ω(c,0.90). If ω > ω(c,0.90),
then:
log(DLT ) = β0 + β1log(F )
where:
F = Observed χ2 statistic across all arms,
β1 =
log(Dˆ0.85,k−1)− log(0.01)
log(F0.85,k−1)− log(F0.99,k−1) ,
β0 = log(0.01)− β1log(F0.99,k−1),
and Fq,k−1 was the critical χ2 value at the qth percentile with k − 1 degrees of freedom. If
ω > ω(c,0.90) and the observed value of D was larger than DLT , then the limited translation
estimate was implemented. In all other instances, the empirical Bayes estimate was used.
The calculation of θLT,S was different for binomial endpoints. A 2x2 table was set
up where the number observed responses used to calculate θMLE,S was fixed. A series of
responses (which were not necessarily integers) were the examined for θLT,S . The one that
resulted in a χ2 statistic closest to DLT was used to estimate θLT,S . As an example, assume
47 responses were observed in the selected arm with 100 patients at the end of stage 2, so
θMLE,S = 0.47. The value for θEB,S was 0.4495, yielding a D value of 0.0846. If the criteria
that ω > ω(c,0.90) was met, and based on F , the D value should not exceed 0.0001. The
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Figure 5.10: log(D) vs log(F ) in study designs with t = 0.5 and a binomial endpoint.
D was the χ2 statistic testing the differences between the MLE and the empirical Bayes
estimates, F was the χ2 statistic testing the differences across all treatment arms, and ω
was the χ2 statistic testing the differences between the MLE and the number of responses
in the arm with the second largest number. Only observations where ω > ω(c,0.90) were
included.
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number of responses for θLT,S needed to be 46.95 in order to have a D value that matched
DLT . As a result, θLT,S = 0.4695.
A comparison of this estimator with others is described later in this dissertation.
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Chapter 6
Comparisons with Previously Proposed Estimators
6.1 Normal Endpoints
The performances of the proposed estimators θˆPB,S and θˆLT,S were compared to the perfor-
mances of three other estimators: the UMVCUE proposed by Bowden and Glimm (2008)
(θˆBG,S), the shrinkage estimator proposed by Carreras and Brannath (2013) (θˆCB,S), and
the proportional prior empirical Bayes estimator with limited translation proposed by Bow-
den et al. (2013) based on principles of meta-analyses (θˆBBG,S). For each simulated trial,
all of the above-mentioned estimators were implemented to allow for a direct comparison
of their performance. Similar to the previous sections, the performance of each of these
estimators was assessed by comparing their bias and RMSE. Since an unbiased estimator
already existed, the goal of this comparison was to assess whether either of the newly
proposed estimators provided a reasonable balance between the two metrics.
The results of this comparison are shown in Figures 6.1, 6.2, and 6.3 for k = 3. Similarly
for k = 5, the results are shown in Figures 6.4, 6.5 and 6.6. An interim analysis occurring
at information fractions (t) between 0.2 and 0.5 were examined as these were upper and
lower limits at which selection was typically conducted. Because various values of t were
examined, any evaluation of bias or RMSE needed to take this into account. To address
this, the mean of the absolute value of the bias over t values between 0.2 and 0.5 (|bias|)
was calculated, as was the mean RMSE over the same values of t (RMSE). These mean
values are summarized for k = 2, 3, 4, and 5 when the largest mean is selected in Tables
6.1 through 6.8. Because the results were fairly consistent across all values of k examined,
the description below summarizes the results from k = 3 and k = 5, unless otherwise
stated. This allowed for comparison of both approaches proposed by Carreras and Brannath
(BLUP and Lindley’s estimator).
For both k = 3 and k = 5, and when the largest mean was selected for stage 2, θˆBG,S
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Figure 6.1: Bias and RMSE of proposed estimators vs UMVCUE in study designs with 3
treatment arms and a normal endpoint (largest stage 1 mean selected).
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Figure 6.2: Bias and RMSE of proposed estimators vs shrinkage estimator in study designs
with 3 treatment arms and a normal endpoint (largest stage 1 mean selected).
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Figure 6.3: Bias and RMSE of proposed estimators vs proportional prior empirical Bayes
estimator in study designs with 3 treatment arms and a normal endpoint (largest stage 1
mean selected).
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Figure 6.4: Bias and RMSE of proposed estimators vs UMVCUE in study designs with 5
treatment arms and a normal endpoint (largest stage 1 mean selected).
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Figure 6.5: Bias and RMSE of proposed estimators vs shrinkage estimator in study designs
with 5 treatment arms and a normal endpoint (largest stage 1 mean selected).
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Figure 6.6: Bias and RMSE of proposed estimators vs proportional prior empirical Bayes
estimator in study designs with 5 treatment arms and a normal endpoint (largest stage 1
mean selected).
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was consistently unbiased (within error) by design with |bias| values approaching 0 for all
four scenarios and both values of k. It also had, however, the large RMSE in all scenarios.
The MLE, θˆMLE,S , had the largest (or in one instance, the second largest) bias based on
|bias|. For the One Active Arm scenario, it had the smallest values of RMSE, but it was
in the bottom half of the estimators for the other three scenarios. In the Equal Means
scenario, θˆLT,S had the second lowest bias (after θˆBG,S) and the smallest RMSE. In the
other three scenarios, however, it had very high RMSE. The performances (both bias and
RMSE) of θˆPB,S , θˆCB,S , and θˆBGG,S were all very similar.
It was clear that there were serious shortcomings to θˆMLE,S (large bias), θˆBG,S (unbi-
ased, but large RMSE), and θˆLT,S (good performance in Equal Means, but large RMSE
elsewhere). Focus was shifted towards evaluating θˆPB,S , θˆCB,S , and θˆBGG,S . In doing
so, there were a number of options to choose from in terms of criteria. Since a common
approach is to examine the RMSE, one could prioritize them based on their average rank
across all four scenarios, where an estimator had a rank of 1 when it had the smallest
RMSE in a scenario and 6 if it had the largest. Calculating the average rank assumed
that all four scenarios should be weighted equally. While some might wish to prioritize
certain scenarios over others, weighing them equally was felt to be reasonable as these
four scenarios captured the extremes in the spectrum of possible mean values. For k = 3,
θˆPB,S had the best average rank for RMSE across all four scenarios, with θˆBGG,S and
θˆCB,S being second and third, respectively. When k = 5, the differences between the three
estimators were smaller with θˆCB,S having the lowest average rank for RMSE, θˆBGG,S
with the second lowest, and θˆPB,S having the third lowest.
The results when the second largest stage 1 mean was selected are shown for k = 3 and
k = 5 in Figures 6.7 through 6.12 and for values of k between 2 and 5 in Tables 6.9 through
6.14. Although the both the bias and RMSE of θˆMLE,S was much improved relative to
the other estimators, it was still a liability when the arm with the largest stage 1 mean
was selected. For this reason, focus was again placed only on θˆPB,S , θˆCB,S , and θˆBGG,S .
When k = 3, θˆBGG,S had the best average rank for RMSE across all four scenarios, with
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θˆPB,S being second best. When k = 5 and the second-best arm was selected, θˆPB,S had
the lowest average rank for RMSE and θˆCB,S had the second lowest.
So by examining RMSE (averaged over t), the performances of θˆPB,S , θˆCB,S , and θˆBGG,S
were all very similar. It was clear that none of them dominated the others.
A second way to evaluate the estimators was to look at the maximum RMSE value at
any t and any scenario and identify the estimator with the lowest value. To be minimax
with respect to R(θ, θˆ), a risk that is equal to the mean squared error, an estimator would
need to meet the criteria:
sup
θ
R(θ, θˆ) = inf
θˆ
sup
θ
R(θ, θˆ)
All possible values of θ and all possible estimators would need to be evaluated, but only
six estimators and a small subset of the sample space of θ was examined. So the approach
described here could only provide evidence on whether an estimator was potentially admis-
sible as a minimax estimator. This again required assuming that all four scenarios (Equal
Means, Linear Means, One Active Arm, and Two Active Arms) were weighted equally,
but this seemed reasonable for the reasons stated above. In addition, the results for a
given value of k when both the largest and second largest stage 1 mean were selected were
pooled together when calculating the maximum observed value. The reason for doing this
was that in many instances, sponsors will not predefine in a protocol whether the largest
or second largest estimator will be selected. They would likely state that the largest would
generally be selected, but allow for the caveat that, if the toxicity profile of the arm with
the largest mean was not reasonable, then the arm with the second largest mean would be
selected. While the exact arm selected may not be pre-specified, the estimator to be used
in the final analysis would typically be. So an estimator should perform well both when
the largest and second largest stage 1 mean was selected.
When k = 2 and the arm with the largest stage 1 mean was selected, θˆMLE,S had the
smallest maximum RMSE value, but it has already been stated that it had unacceptable
bias, particularly in the Equal Means scenario. The estimator with the second smallest
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Figure 6.7: Bias and RMSE of proposed estimators vs UMVCUE in study designs with 3
treatment arms and a normal endpoint (second largest stage 1 mean selected).
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Figure 6.8: Bias and RMSE of proposed estimators vs shrinkage estimator in study designs
with 3 treatment arms and a normal endpoint (second largest stage 1 mean selected).
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Figure 6.9: Bias and RMSE of proposed estimators vs proportional prior empirical Bayes
estimator in study designs with 3 treatment arms and a normal endpoint (second largest
stage 1 mean selected).
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Figure 6.10: Bias and RMSE of proposed estimators vs UMVCUE in study designs with 5
treatment arms and a normal endpoint (second largest stage 1 mean selected).
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Figure 6.11: Bias and RMSE of proposed estimators vs shrinkage estimator in study designs
with 5 treatment arms and a normal endpoint (second largest stage 1 mean selected).
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Figure 6.12: Bias and RMSE of proposed estimators vs proportional prior empirical Bayes
estimator in study designs with 5 treatment arms and a normal endpoint (second largest
stage 1 mean selected).
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maximum value was θˆPB,S . In the case where k = 2 and the second best arm was selected,
all of the estimators (with the exception of θˆBG,S) were equivalent to θˆMLE,S since the larger
arm was removed when the bias adjustment was conducted. For k = 3 and combining the
results when the largest and second largest means were selected, θˆMLE,S had the smallest
maximum RMSE and θˆPB,S had the second smallest. For k = 4, θˆPB,S had the smallest
maximum RMSE value, and for k = 5, θˆPB,S had the second smallest behind θˆCB,S . Doing
this same exercise for the absolute value of the bias showed that with three or more arms,
θˆPB,S had the second smallest maximum bias after the unbiased θˆBG,S .
A third approach to comparing estimators that is sometimes used is to compute each
estimator’s efficiency relative to the Cramer-Rao lower bound (CRLB):
% efficiency =
σ2CRLB
σ2
θˆ
∗ 100%
σ2CRLB was defined as:
σ2CRLB =
(
d
dθE[θ]
)2
nI(θ)
where I(θ) was the Fisher Information and was defined as:
I(θ) = V ar
(
∂
∂θ
log(f(x, θ))
)
In the case of treatment selection designs, the distribution of the largest stage 1 mean,
depending on the value of θ = (θ1, ..., θk), the number of patients per arm in stage 1, as well
as the number of arms (Figure 6.13). This created a problem in that the CRLB could change
as t, k, and θ vary. In some instances, the distribution approached a normal one, while in
a number of scenarios, the distribution was skewed. So calculating the relative efficiency
was not necessarily informative (or feasible) in this design as there would potentially be
countless RCLB values.
A subset of the estimators was further examined by comparing their performance when
the correct arm (i.e. the one with the largest true mean, max(θ1, ..., θk)) was selected versus
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Figure 6.13: Distribution of largest stage 1 mean across various scenarios
Estimator Two
Active
Arms
One Active
Arm
Max
MLE 0.0334 0.0087 0.0400
UMVCUE 0.0005 0.0006 0.0010
CB 0.0114 0.0132 0.0198
BGG 0.0132 0.0143 0.0205
PB 0.0187 0.0029 0.0221
LT 0.0097 0.0093 0.0115
Table 6.1: Comparison of |bias| values in study designs with 2 treatment arms and a normal
endpoint (largest stage 1 mean selected). The mean of the absolute bias was taken across
values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed was
the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
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Estimator Two
Active
Arms
One Active
Arm
Max
MLE 0.1000 0.1005 0.1016
UMVCUE 0.1105 0.1032 0.1165
CB 0.0939 0.1033 0.1071
BGG 0.0909 0.1058 0.1093
PB 0.0959 0.1026 0.1056
LT 0.0914 0.1113 0.1158
Table 6.2: Comparison of RMSE values in study designs with 2 treatment arms and a
normal endpoint (largest stage 1 mean selected). The mean of the RMSE was taken across
values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed was
the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0495 0.0270 0.0347 0.0143 0.0598
UMVCUE 0.0004 0.0009 0.0006 0.0010 0.0025
CB 0.0121 0.0094 0.0023 0.0230 0.0319
BGG 0.0264 0.0047 0.0135 0.0073 0.0310
PB 0.0249 0.0045 0.0082 0.0045 0.0298
LT 0.0114 0.0083 0.0060 0.0084 0.0131
Table 6.3: Comparison of |bias| values in study designs with 3 treatment arms and a normal
endpoint (largest stage 1 mean selected). The mean of the absolute bias was taken across
values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed was
the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.1050 0.1010 0.1010 0.1010 0.1059
UMVCUE 0.1137 0.1082 0.1114 0.1049 0.1192
CB 0.0919 0.1004 0.0971 0.1064 0.1115
BGG 0.0909 0.1009 0.0981 0.1048 0.1069
PB 0.0958 0.0999 0.0971 0.1037 0.1069
LT 0.0856 0.1116 0.1057 0.1170 0.1202
Table 6.4: Comparison of RMSE values in study designs with 3 treatment arms and a
normal endpoint (largest stage 1 mean selected). The mean of the RMSE was taken across
values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed was
the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0608 0.0382 0.0367 0.0195 0.0736
UMVCUE 0.0009 0.0009 0.0006 0.0008 0.0016
CB 0.0371 0.0203 0.0219 0.0057 0.0449
BGG 0.0390 0.0177 0.0184 0.0059 0.0465
PB 0.0293 0.0087 0.0077 0.0048 0.0356
LT 0.0143 0.0070 0.0041 0.0053 0.0164
Table 6.5: Comparison of |bias| values in study designs with 4 treatment arms and a normal
endpoint (largest stage 1 mean selected). The mean of the absolute bias was taken across
values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed was
the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.1095 0.1028 0.1006 0.1017 0.1128
UMVCUE 0.1151 0.1108 0.1102 0.1057 0.1225
CB 0.0993 0.0992 0.0976 0.1017 0.1038
BGG 0.0936 0.0990 0.0979 0.1031 0.1052
PB 0.0959 0.0985 0.0970 0.1039 0.1078
LT 0.0813 0.1104 0.1117 0.1179 0.1220
Table 6.6: Comparison of RMSE values in study designs with 4 treatment arms and a
normal endpoint (largest stage 1 mean selected). The mean of the RMSE was taken across
values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed was
the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0678 0.0474 0.0381 0.0243 0.0825
UMVCUE 0.0005 0.0010 0.0005 0.0006 0.0019
CB 0.0316 0.0181 0.0128 0.0092 0.0387
BGG 0.0326 0.0115 0.0051 0.0113 0.0396
PB 0.0313 0.0129 0.0077 0.0046 0.0384
LT 0.0152 0.0040 0.0022 0.0033 0.0180
Table 6.7: Comparison of |bias| values in study designs with 5 treatment arms and a normal
endpoint (largest stage 1 mean selected). The mean of the absolute bias was taken across
values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed was
the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.1133 0.1063 0.1019 0.1033 0.1190
UMVCUE 0.1165 0.1132 0.1113 0.1075 0.1253
CB 0.0966 0.0988 0.0974 0.1035 0.1069
BGG 0.0865 0.0982 0.0988 0.1068 0.1102
PB 0.0965 0.0988 0.0986 0.1051 0.1096
LT 0.0784 0.1104 0.1156 0.1197 0.1248
Table 6.8: Comparison of RMSE values in study designs with 5 treatment arms and a
normal endpoint (largest stage 1 mean selected). The mean of the RMSE was taken across
values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed was
the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0006 0.0011 0.0196 0.0195 0.0311
UMVCUE 0.0008 0.0012 0.0013 0.0010 0.0020
CB 0.0196 0.0235 0.0432 0.0038 0.0595
BGG 0.0231 0.0237 0.0431 0.0040 0.0588
PB 0.0121 0.0125 0.0301 0.0069 0.0421
LT 0.0287 0.0271 0.0443 0.0061 0.0564
Table 6.9: Comparison of |bias| values in study designs with 3 treatment arms and a normal
endpoint (second largest stage 1 mean selected). The mean of the absolute bias was taken
across values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed
was the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0896 0.0983 0.0976 0.0985 0.0993
UMVCUE 0.1180 0.1136 0.1124 0.1129 0.1292
CB 0.0912 0.1018 0.1069 0.0957 0.1138
BGG 0.0884 0.1033 0.1098 0.0934 0.1163
PB 0.0903 0.0997 0.1016 0.0967 0.1052
LT 0.0898 0.1087 0.1162 0.0956 0.1222
Table 6.10: Comparison of RMSE values in study designs with 3 treatment arms and a
normal endpoint (second largest stage 1 mean selected). The mean of the RMSE was taken
across values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed
was the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0172 0.0088 0.0113 0.0330 0.0472
UMVCUE 0.0018 0.0006 0.0013 0.0012 0.0034
CB 0.0151 0.0275 0.0495 0.0046 0.0683
BGG 0.0093 0.0155 0.0328 0.0098 0.0470
PB 0.0035 0.0115 0.0284 0.0121 0.0403
LT 0.0259 0.0337 0.0413 0.0064 0.0522
Table 6.11: Comparison of |bias| values in study designs with 4 treatment arms and a
normal endpoint (second largest stage 1 mean selected). The mean of the absolute bias
was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0900 0.0969 0.0984 0.1019 0.1056
UMVCUE 0.1208 0.1175 0.1143 0.1167 0.1330
CB 0.0886 0.1015 0.1120 0.0954 0.1217
BGG 0.0836 0.1001 0.1080 0.0924 0.1128
PB 0.0881 0.0979 0.1034 0.0972 0.1075
LT 0.0838 0.1114 0.1225 0.0922 0.1286
Table 6.12: Comparison of RMSE values in study designs with 4 treatment arms and a
normal endpoint (second largest stage 1 mean selected). The mean of the RMSE was taken
across values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed
was the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0294 0.0176 0.0089 0.0420 0.0574
UMVCUE 0.0004 0.0009 0.0002 0.0015 0.0026
CB 0.0048 0.0034 0.0242 0.0182 0.0401
BGG 0.0043 0.0049 0.0239 0.0201 0.0401
PB 0.0030 0.0079 0.0255 0.0158 0.0400
LT 0.0213 0.0338 0.0358 0.0051 0.0491
Table 6.13: Comparison of |bias| values in study designs with 5 treatment arms and a
normal endpoint (second largest stage 1 mean selected). The mean of the absolute bias
was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0919 0.0963 0.0995 0.1045 0.1091
UMVCUE 0.1213 0.1186 0.1157 0.1176 0.1331
CB 0.0875 0.0959 0.1039 0.0979 0.1079
BGG 0.0810 0.0965 0.1059 0.0931 0.1097
PB 0.0868 0.0959 0.1044 0.0971 0.1087
LT 0.0776 0.1110 0.1237 0.0897 0.1306
Table 6.14: Comparison of RMSE values in study designs with 5 treatment arms and a
normal endpoint (second largest stage 1 mean selected). The mean of the RMSE was taken
across values of t ranging from 0.2 to 0.5 within each scenario. The maximum value listed
was the maximum observed value at any value of t (between 0.2 and 0.5) in any of the four
scenarios.
when the incorrect arm was selected in designs with five arms. As discussed above, θˆBG,S
was unbiased, but had elevated RMSE. This did not change when the data was divided
based on whether the correct arm was selected. Similarly, the MLE had large bias in most
scenarios, which also did not change when dividing the data in this manner. Because of
this, these two estimators were not examined further in this comparison. Good overall bias
adjustment had been previously observed with θˆLT,S . A closer inspection, however, showed
that it consistently under-estimated the mean when the correct arm was selected and over-
estimated it when the incorrect arm was selected (Figures 6.14 and 6.16). It also had
much higher RMSE than the other estimators when the correct arm was selected (Figures
6.15 and 6.17). Much like the results above, θˆPB,S , θˆCB,S , and θˆBGG,S had similar RMSE,
particularly when the correct arm was selected. The bias of θˆPB,S was slightly better than
at least one of the other two estimators in all three scenarios, suggesting that this favorable
bias came at the expense of increased variance since the RMSE values were so similar. The
advantage of θˆPB,S was more evident when the incorrect arm was selected. All of the
estimators over-estimated the mean when the incorrect arm was selected, but with k = 3,
the RMSE for θˆPB,S and θˆCB,S (using the mixed-effects model) were very similar to one
another and both markedly lower than the other estimators in the Two Active Arm and
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One Active Arm scenarios. With k = 5, θˆPB,S had similar RMSE to θˆCB,S (using Lindley’s
estimator) and θˆBGG,S in the Linear Means scenario, but the RMSE of θˆPB,S was smaller
than θˆCB,S and θˆBGG,S in the other two scenarios. So in addition to the characteristics
described above, θˆPB,S also had the added benefit of having reduced RMSE in the case
where the wrong arm was selected for stage 2. These results also illustrated the negative
consequences of selecting the incorrect arm for stage 2.
In summary, there was no estimator that dominated the rest. It was confirmed that
θˆMLE,S had large bias, with the exception of the One Active Arm Scenario. θˆBG,S was
unbiased, but had generally elevated RMSE. θˆLT,S performed very well in the Equal Means
scenario, but had elevated RMSE in the other scenarios. θˆCB,S , θˆBGG,S , and θˆPB,S all had
very similar and reasonable performance. θˆPB,S was consistently one of the two estimators
with the smallest maximum RMSE across values of t between 0.2 and 0.5. It also had
a small maximum bias, particularly when k ≥ 3. θˆPB,S also better handled the situation
where an incorrect arm was selected for stage 2. So based on these results, there was strong
evidence suggesting that θˆPB,S could be used for estimation in treatment selection designs
with normal endpoints.
6.2 Binomial Endpoint
Much like the normally distributed endpoints, the maximum likelihood estimator,
θˆMLE,S =
XS + Y
n1 + n2
,
can lead to a biased estimate due to the selection method. For studies with a binomial
endpoint, the parametric bootstrap and the limited translation approaches were compared
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Figure 6.14: Bias of estimators when the correct and incorrect arms were selected in study
designs with 3 treatment arms and a normal endpoint.
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Figure 6.15: RMSE of estimators when the correct and incorrect arms were selected in
study designs with 3 treatment arms and a normal endpoint.
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Figure 6.16: Bias of estimators when the correct and incorrect arms were selected in study
designs with 5 treatment arms and a normal endpoint.
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Figure 6.17: RMSE of estimators when the correct and incorrect arms were selected in
study designs with 5 treatment arms and a normal endpoint.
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to the MLE and the UMVUE described by Tappin (1992):
θˆT,S =

X(1)+Y
n1+n2
if (X(1) + Y )−X(2) > n2
1
n2
∑(X(1)+Y )−X(2)
Y=0 Y (
n2
Y )(
n1
X(1)
)∑(X(1)+Y )−X(2)
Y=0 (
n2
Y )(
n1
X(1)
)
if (X(1) + Y )−X2 ≤ n2 and i1 < i2
1
n2
∑(X(1)+Y )−X(2)−1
Y=0 Y (
n2
Y )(
n1
X(1)
)∑(X(1)+Y )−X(2)−1
Y=0 (
n2
Y )(
n1
X(1)
)
if (X(1) + Y )−X(2) ≤ n2 and i1 > i2.
where i was the index of the arms. In the case where the second best arm was of interest,
the arm with the largest number of responses was removed and the study was treated as if
it only had k − 1 arms. In the case of ties, the removed arm was the one with the largest
index.
Figure 6.18 displays the results from the design with three treatment arms, Figure 6.19
displays the results from the design with five treatment arms, and Figures 6.20 and 6.21
display the results from the design with where the second-best arm was selected with k = 3
and k = 5. Overall, the bias was lower compared to normally distributed endpoints. For
example, with three treatment arms and t = 0.5, normally distributed endpoints showed
a relative bias (compared to the true mean) of 15% when the MLE was used in the Equal
Means Scenario, but the binomial endpoint exhibited less than 10% bias under the same
conditions. With the exception of θˆMLE,S , the average estimated proportions were all
within 0.02 of the true proportion.
Similar to the analysis of the normally distributed endpoint, the mean bias, |bias|, and
mean RMSE, RMSE, were calculated to allow for the comparisons of the estimators across
the various values of t. The values are found in Tables 6.15 through 6.22 for designs where
the arm with the largest number of responses was selected for stage 2 and k = 2, 3, 4,
and 5. With this selection approach, θˆPB,S had reduced bias compared to θˆMLE,S , but
θˆT,S and θˆLT,S both had minimal bias across the four scenarios. In terms of RMSE, θˆT,S
had consistently elevated values, while θˆPB,S had the smallest RMSE value in the Equal
Means, Linear Means, and Two Active Arms scenario across all values of k. It had the
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Estimator Two
Active
Arms
One Active
Arm
Max
MLE 0.0161 0.0012 0.0196
UMCUE 0.0006 0.0012 0.0018
PB 0.0090 0.0012 0.0108
LT 0.0027 0.0031 0.0047
Table 6.15: Comparison of |bias| values in study designs with 2 treatment arms and a
binomial endpoint (largest number of stage 1 responses selected). The mean of the absolute
bias was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
second smallest AUCRMSE in the One Active Arm scenario behind θˆMLE,S .
The |bias| and RMSE values for designs where the second largest number of responses
were selected for stage 2 and k = 2, 3, 4, and 5 are found in Tables 6.23 through 6.28. In
terms of bias, the performance of the various estimators was dependent upon the scenario,
but θˆPB,S had the best or second best average rank across the four scenarios for |bias|
across all values of k examined. The same was also true of RMSE. It was curious to
note that θˆT,S was not unbiased in all scenarios when the second best arm was selected.
This was possibly due to the fact that XS could not be any larger than the largest number
of responses, so the values included in the summations were underestimated compared to
the event where there really were only k − 1 arms in the study. This could explain the
consistent underestimation of the effect with θˆT,S .
The results when selecting the best and second-best arms were pooled and the maximum
values were also examined. θˆPB,S had the smallest maximum RMSE value across all values
of k. It also had the second smallest maximum absolute bias after θˆT,S .
When comparing the performance when the correct and incorrect arms were selected
with k = 5 (Figures 6.22 and 6.23), the observed performance was similar to that observed
with normal endpoints. θˆPB,S , θˆLT,S , and θˆT,S had minimal bias when the correct arm was
selected, but the bias of θˆPB,S and θˆLT,S increased when an incorrect arm was selected.
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Figure 6.18: Bias and RMSE using θˆMLE,S , θˆPB,S , θˆLT,S , and θˆT,S in study designs with 3
treatment arms and a binomial endpoint (largest number of stage 1 responses selected).
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Figure 6.19: Bias and RMSE using θˆMLE,S , θˆPB,S , θˆLT,S , and θˆT,S in study designs with 5
treatment arms and a binomial endpoint (largest number of stage 1 responses selected).
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Figure 6.20: Bias and RMSE using θˆMLE,S , θˆPB,S , θˆLT,S , and θˆT,S in study designs with
3 treatment arms and a binomial endpoint (second largest number of stage 1 responses
selected).
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Figure 6.21: Bias and RMSE using θˆMLE,S , θˆPB,S , θˆLT,S , and θˆT,S in study designs with
5 treatment arms and a binomial endpoint (second largest number of stage 1 responses
selected).
106
Estimator Two
Active
Arms
One Active
Arm
Max
MLE 0.0487 0.0481 0.0503
UMCUE 0.0532 0.0481 0.0549
PB 0.0466 0.0482 0.0490
LT 0.0472 0.0483 0.0493
Table 6.16: Comparison of RMSE values in study designs with 2 treatment arms and a
binomial endpoint (largest number of stage 1 responses selected). The mean of the RMSE
was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0241 0.0140 0.0172 0.0078 0.0280
UMVUE 0.0011 0.0007 0.0006 0.0008 0.0019
PB 0.0122 0.0025 0.0046 0.0017 0.0151
LT 0.0045 0.0011 0.0025 0.0033 0.0068
Table 6.17: Comparison of |bias| values in study designs with 3 treatment arms and a
binomial endpoint (largest number of stage 1 responses selected). The mean of the absolute
bias was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0512 0.0478 0.0488 0.0475 0.0517
UMVUE 0.0548 0.0514 0.0532 0.0495 0.0576
PB 0.0466 0.0471 0.0466 0.0488 0.0512
LT 0.0475 0.0481 0.0479 0.0492 0.0519
Table 6.18: Comparison of RMSE values in study designs with 3 treatment arms and a
binomial endpoint (largest number of stage 1 responses selected). The mean of the RMSE
was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0294 0.0199 0.0182 0.0108 0.0358
UMVUE 0.0006 0.0004 0.0012 0.0011 0.0024
PB 0.0143 0.0050 0.0042 0.0018 0.0174
LT 0.0039 0.0011 0.0018 0.0021 0.0051
Table 6.19: Comparison of |bias| values in study designs with 4 treatment arms and a
binomial endpoint (largest number of stage 1 responses selected). The mean of the absolute
bias was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0537 0.0489 0.0484 0.0482 0.0551
UMVUE 0.0562 0.0524 0.0527 0.0504 0.0592
PB 0.0471 0.0463 0.0464 0.0494 0.0514
LT 0.0477 0.0481 0.0486 0.0504 0.0527
Table 6.20: Comparison of RMSE values in study designs with 4 treatment arms and a
binomial endpoint (largest number of stage 1 responses selected). The mean of the RMSE
was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0331 0.0246 0.0180 0.0123 0.0391
UMVUE 0.0006 0.0011 0.0017 0.0011 0.0032
PB 0.0154 0.0073 0.0032 0.0023 0.0176
LT 0.0021 0.0012 0.0011 0.0027 0.0038
Table 6.21: Comparison of |bias| values in study designs with 5 treatment arms and a
binomial endpoint (largest number of stage 1 responses selected). The mean of the absolute
bias was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0550 0.0507 0.0486 0.0480 0.0574
UMVUE 0.0561 0.0534 0.0533 0.0498 0.0609
PB 0.0467 0.0466 0.0472 0.0488 0.0520
LT 0.0472 0.0489 0.0505 0.0509 0.0546
Table 6.22: Comparison of RMSE values in study designs with 5 treatment arms and a
binomial endpoint (largest number of stage 1 responses selected). The mean of the RMSE
was taken across values of t ranging from 0.2 to 0.5 within each scenario. The maximum
value listed was the maximum observed value at any value of t (between 0.2 and 0.5) in
any of the four scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0006 0.0017 0.0083 0.0093 0.0139
UMVUE 0.0137 0.0082 0.0139 0.0033 0.0187
PB 0.0059 0.0040 0.0136 0.0043 0.0193
LT 0.0135 0.0105 0.0183 0.0046 0.0247
Table 6.23: Comparison of |bias| values in study designs with 3 treatment arms and a
binomial endpoint (second largest number of stage 1 responses selected). The mean of the
absolute bias was taken across values of t ranging from 0.2 to 0.5 within each scenario.
The maximum value listed was the maximum observed value at any value of t (between
0.2 and 0.5) in any of the four scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0436 0.0441 0.0462 0.0405 0.0471
UMVUE 0.0520 0.0477 0.0483 0.0442 0.0547
PB 0.0438 0.0448 0.0483 0.0395 0.0500
LT 0.0470 0.0460 0.0496 0.0408 0.0523
Table 6.24: Comparison of RMSE values in study designs with 3 treatment arms and
a binomial endpoint (second largest number of stage 1 responses selected). The mean of
the RMSE was taken across values of t ranging from 0.2 to 0.5 within each scenario. The
maximum value listed was the maximum observed value at any value of t (between 0.2 and
0.5) in any of the four scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0080 0.0073 0.0049 0.0158 0.0207
UMVUE 0.0128 0.0093 0.0129 0.0033 0.0176
PB 0.0016 0.0026 0.0117 0.0075 0.0188
LT 0.0117 0.0097 0.0158 0.0040 0.0228
Table 6.25: Comparison of |bias| values in study designs with 4 treatment arms and a
binomial endpoint (second largest number of stage 1 responses selected). The mean of the
absolute bias was taken across values of t ranging from 0.2 to 0.5 within each scenario.
The maximum value listed was the maximum observed value at any value of t (between
0.2 and 0.5) in any of the four scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0440 0.0442 0.0460 0.0419 0.0472
UMVUE 0.0540 0.0496 0.0491 0.0450 0.0576
PB 0.0430 0.0444 0.0485 0.0395 0.0514
LT 0.0469 0.0462 0.0500 0.0406 0.0540
Table 6.26: Comparison of RMSE values in study designs with 4 treatment arms and
a binomial endpoint (second largest number of stage 1 responses selected). The mean of
the RMSE was taken across values of t ranging from 0.2 to 0.5 within each scenario. The
maximum value listed was the maximum observed value at any value of t (between 0.2 and
0.5) in any of the four scenarios.
Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0132 0.0114 0.0036 0.0192 0.0250
UMVUE 0.0125 0.0099 0.0124 0.0039 0.0172
PB 0.0010 0.0015 0.0105 0.0087 0.0165
LT 0.0128 0.0107 0.0150 0.0059 0.0206
Table 6.27: Comparison of |bias| values in study designs with 5 treatment arms and a
binomial endpoint (second largest number of stage 1 responses selected). The mean of the
absolute bias was taken across values of t ranging from 0.2 to 0.5 within each scenario.
The maximum value listed was the maximum observed value at any value of t (between
0.2 and 0.5) in any of the four scenarios.
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Estimator Equal
Means
Linear
Means
Two
Active
Arms
One Active
Arm
Max
MLE 0.0448 0.0448 0.0454 0.0435 0.0465
UMVUE 0.0549 0.0509 0.0487 0.0460 0.0591
PB 0.0425 0.0441 0.0479 0.0401 0.0502
LT 0.0475 0.0472 0.0500 0.0413 0.0535
Table 6.28: Comparison of RMSE values in study designs with 5 treatment arms and
a binomial endpoint (second largest number of stage 1 responses selected). The mean of
the RMSE was taken across values of t ranging from 0.2 to 0.5 within each scenario. The
maximum value listed was the maximum observed value at any value of t (between 0.2 and
0.5) in any of the four scenarios.
θˆPB,S also had relatively low RMSE, particularly in the Linear Means and Two Active
Arms scenarios, when the correct arm was selected. When the incorrect arm was selected,
θˆPB,S had reduced bias and RMSE compared to θˆMLE,S , but θˆLT,S actually performed
slightly better.
In addition to θˆMLE,S , θˆT,S , and θˆLT,S , the performance of θˆPB,S was also compared to
the stepwise overcorrection method described by Shen (2001). The recommended value of
γ = 2 was examined as well as values of 1 and 4. The two estimators had similar RMSE in
each scenario, but the bias of the stepwise overcorrection method was improved over that
of θˆPB,S in the Equal Means scenario. The bias of the two estimators was comparable in
the Two Active Arms scenario, but θˆPB,S showed improved bias in the Linear Means and
One Active Arm scenarios. Values of γ < 1 for the stepwise overcorrection method would
further increase the bias in the Equal Means scenario and the Two Active Arms scenario,
while bringing the estimate closer to unbiased in the other two scenarios. These results
indicated that θˆPB,S was comparable or superior to the estimator proposed by Shen when
there were differences among the true means.
The totality of the results suggested that θˆLT,S had slightly less bias than θˆPB,S when
the largest mean was selected, but it generally had higher RMSE. Similar to the normal
endpoint, θˆMLE,S had bias that was prohibitive while the unbiased θˆT,S had substantial
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Figure 6.22: Bias of estimators when correct and incorrect arms were selected in study
designs with 5 treatment arms and a binomial endpoint.
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Figure 6.23: RMSE of estimators When correct and incorrect arms were selected in study
designs with 5 treatment arms and a binomial endpoint.
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Equal Means Linear Means Two Active Arms One Active Arm
Bias RMSE Bias RMSE Bias RMSE Bias RMSE
PB 0.014 0.045 0.000 0.048 0.003 0.046 -0.002 0.051
Shen (γ = 1) 0.006 0.044 -0.002 0.048 0.003 0.046 -0.005 0.052
Shen (γ = 2) 0.003 0.043 -0.006 0.049 -0.001 0.046 -0.009 0.053
Shen (γ = 4) 0.002 0.042 -0.011 0.047 -0.004 0.045 -0.019 0.052
Table 6.29: Comparison of the parametric bootstrap estimator and the stepwise overcor-
rection method in study designs with 3 treatment arms, t = 0.5, and a binomial endpoint.
RMSE. When the second largest number of responses was selected, the performance (both
bias and RMSE) of θˆPB,S was preferable over the other three estimators. In addition, the
performance of θˆPB,S was favorable compared to the estimator proposed by Shen (2001),
particularly when there were differences among the true means. While either θˆPB,S or θˆLT,S
would be a reasonable choice for treatment-selection designs, a slight edge could be given
to θˆPB,S especially when factoring in its performance with normally distributed endpoints.
It was viewed as valuable if the same estimator could be used across a wide range of study
types so long as the performance supported its use.
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Chapter 7
Additional Considerations for Treatment-Selection Designs
7.1 Confidence Intervals
7.1.1 Normal Endpoints
While accurate estimation of the effect size is a critical characteristic of any estimator,
a measure of its variability is also often needed. Sampson and Sill (2005) identified a
Uniformly Most Powerful Conditionally Unbiased (UMPCU) test for a one-sided hypothesis
comparing the selected treatment arm to a control arm (H0 : θS − θ0 ≤ ∆10). As Bowden
and Glimm (2008) subsequently did, they found the joint distribution of the stage 1 means
of each arm and the stage 2 mean of the selected arm (X and Y , respectively) given Q,
the observed order statistics for the stage 1 means. For simplicity, Q was assumed to be
the event that {X : X1 > X2 > ... > Xk}. Sampson and Sill then rearranged this to be
the joint distribution of X and Z given Q (denoted f(Z,X|Q)), where Z = n1X1 + n2Y .
They then found the joint distribution of XC and Z given Q, where XC was the set of
stage 1 means not selected for stage 2 (XC = (X2, ..., Xk)):
f(Z,XC |Q) =
∫ ∞
X2
f(Z,X|Q)dX1
= C(n1, n2, σ)K(θ)
−1IQ(XC)φ
[
Z − (n1 + n2)θS
σ
√
n1 + n2
]
Φ
[√
n1Z − (n1 + n2)X2
σ
√
n2(n1 + n2)
]
Π
where C(n1, n2, σ) =
n
k/2
1
σk
√
n1(n1+n2)
, Π =
∏k
i=2 φ
[√
n1(Xi−θi)
σ
]
, IQ(X
C) was the indicator
function for {XC : X2 > X3 > ... > Xk}, and K(θ) was the probability of observing event
Q. They then found the joint distribution f(θˆMLE,S ,X
C , Y0|Q):
f(θˆMLE,S ,X
C , Y0|Q) = C∆(θ, σ)φ
[√
n1 + n2(θˆMLE,S − θS)
σ
]
φ
[√
n0(Y0 − θ0)
σ
]
Υ
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where Y0 was the observed mean of the n0 control observations at the end of the study,
Υ = Φ
[√
n1(n1 + n2)(θˆMLE,S −X2)√
n2σ
]
Π,
C∆(θ, σ) =
n
k/2
1
√
n1 + n2
σk
√
n1
K(θ)−1IQ(XC),
and Π, K(θ), and IQ(X
C) were as described above. They then noted that this was a
(k + 1)-dimensional exponential distribution where the exponent was of the form:
∆1W + %T +
k∑
i=2
θiXi.
The parameter of interest in this case was ∆1 = θS − θ0 with test statistic:
W =
n0(n1 + n2)
(n0 + n1 + n2)σ2
(
θˆMLE,S − Y0
)
The nuisance parameters were therefore (θ2, ., θk) and
% =
n0θ0 + (n1 + n2)θ1
σ2
,
while
T =
n0Y0 + (n1 + n2)θˆMLE,S
n0 + n1 + n2
.
Having defined this, they then identified the distribution of W,T,XC |Q and W |XC , T,Q:
f(W |XC , T,Q) = f(W,X
C , T |Q)∫∞
−∞ f(W,X
C , T |Q)dW ,
and identified the critical values of W to make it an α-level test for the null hypothesis
H0 : ∆1 = 0. They also inverted this test to define a 100 ∗ (1− α)% confidence interval.
It has been recommended that the confidence interval of Sampson and Sill be used
to estimate the variability of other previously proposed estimators (e.g. Carreras and
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Brannath (2013)). In the simulation studies described in the previous sections, the actual
treatment means were estimated instead of the mean difference from a control arm. Much
of the work of Sampson and Sill built upon that of Cohen and Sackrowitz (1989) and
the Ph.D. dissertation of Sill (Sill (2000)). In his dissertation, he took f(Z,XC |Q) and
included the distributions of X3, ..., Xk into the normalization constant:
f(Z,XC |Q) = CNφ
[
Z − (n1 + n2)θS
σ
√
n1 + n2
]
Φ
[√
n1Z − (n1 + n2)X2
σ
√
n2(n1 + n2)
]
,
where CN was the normalization constant. Separate CN values were calculated across a
range of θS values by inserting the current value of θS and the observed values of X
C ,
integrating across all possible values of Z, and then taking the inverse of the result.
Using the calculated values of CN and the observed values of X
C , Sill calculated the
probability of Z being less than the observed Z, Z < Zobs, given Q for a range of θS values:
Pr(Z < Zobs) =
∫ Zobs
−∞
f(Z,XC |Q, θS)
The 95% confidence interval was then defined as the values of θS where Pr(Z < Zobs) =
0.025 and 0.975.
The confidence interval described in Sill (2000) was further evaluated here. It was of
interest to understand the coverage probabilities of this confidence interval, and how they
compared to a newly proposed confidence interval around θˆPB,S .
7.1.1.1 Proposed Confidence Intervals for Parametric Bootstrap Estimator
When estimating a confidence interval for the parametric bootstrap estimator, a logical
choice was to use a bootstrap approach. Care needed to be taken when calculating this
to ensure that the interval correctly captured the parameter of interest. Such a confidence
interval should capture the uncertainty of the true mean of the selected arm, θS . To address
this, the following steps were taken:
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1. SampleX
(m)
i , i = 1, ..., k from aN(Gi, σ
2/n1) distribution, whereGi was the observed
MLE of θi. When i = S,Gi = θˆMLE,S , otherwise Gi = Xi.
2. Calculate pˆ
(m)
(1)i for each of the k arms using the approach previously described for
normal endpoints
3. Sample Y (m) from a N(GS(m) , σ
2/n2) distribution, where GS(m) was the observed
MLE of the arm selected to have the largest mean in bootstrap m. Note that the arm
selected in the bootstrap sample may not be the same arm selected in the observed
study data.
4. Calculate θˆ
(m)
PB,S using X
(m)
1 , ..., X
(m)
k , Y
(m), and pˆ
(m)
(1)1, ..., pˆ
(m)
(1)k
5. Identify the bootstrapped value of the selected arm. If S(m) equaled the observed
selected arm, S, then θˆ
(m)
PB,S was used. Otherwise, X
(m)
S was used.
6. For a 95% confidence interval, CPB(x), calculate the 2.5
th and 97.5th percentiles of
the G
(m)
S values
It was important to calculate this confidence interval based on G
(m)
S and not on θˆ
(m)
PB,S .
Using G
(m)
S ensured that the confidence interval provided an estimate of the uncertainty
around θS . Using θˆ
(m)
PB,S would instead provide the uncertainty of the largest true mean,
θ(1). This latter confidence interval was not used since an estimate of θ(1) after the selection
had already occurred was not of interest.
Morris (1983) identified an estimate for the variance of Stein’s estimator and then
defined a confidence region for a group of k empirical Bayes estimators as Ck(X) satisfying
Pr(θi ∈ Ck(X)) ≥ 1−α. Laird and Louis (1987) extended this research and identified three
bootstrap approaches that estimated confidence intervals for one of the k empirical Bayes
estimates. Each of the three approaches incrementally increased the number of parametric
assumptions that were required. The “Type I” confidence intervals employed the traditional
non-parametric bootstrap approach where a large number of samples were drawn from the
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empirical distribution of the data and θi was estimated by θˆi. The distribution of the prior
pi(θi|Xi, ψˆ), where ψˆ were the estimated prior parameters, had no parametric assumptions.
The “Type II” confidence intervals assumed a parametric form for f(Xi|θi), but there
was no parametric assumption on pi(θi|Xi, ψˆ). Finally, the “Type III” confidence intervals
made parametric assumptions on both f(Xi|θi) and pi(θi|Xi, ψˆ). Using this third type
of confidence interval, they proposed sampling k values of θ∗i from pi(θi|Xi, ψˆ) and then
drawing k values of X∗i from f(Xi|θ∗i ).
For all three approaches, the estimated variance of θˆi had to incorporate the variability
of estimating both Xi and θi from the data. To address this, Laird and Louis made use of
the definition for conditional variance where
V ar(Y ) = E[V ar(Y |X)] + V ar(E[Y |X])
Using M bootstrapped samples, the estimated variance of θˆi was therefore defined as:
V ar(θˆi) =
∑M
m=1 V ar(θˆ
(m)
i |X(m)i , σ2, ψˆ(m))
M
+
∑M
m=1(θˆ
(m)
i − θ
∗
i )
2
M − 1
where θˆ
(m)
i , X
(m)
i , and ψˆ
(m) represented a single resampled value of θˆi, Xi, and ψˆ, and θ
∗
i
represented the average of all M bootstrapped estimates of θi.
While θˆPB,S was not an empirical Bayes estimator, it was thought that the “Type III”
confidence interval of Laird and Louis could be applicable as the variance of GS needed
to incorporate the variance of all k stage 1 means, the variance of the stage 2 mean, as
well as the variability of estimating all p(1)i values. Further investigation of this, however,
showed that a confidence interval for GS calculated in this manner was very wide, resulting
in coverage probabilities that were too high. Adding to this was the fact that G
(m)
S could
have varying numbers of patients contributing to it depending on whether it was selected
for stage 2. This prevented the first term of V ar(θˆi) from being an accurate estimate. This
confidence interval was, therefore, not pursued further.
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7.1.1.2 Comparison of Various Confidence Intervals
The proposed confidence interval, CPB(x), was compared to that of Sill (CSill(x)) with
respect to their coverage probability, defined as Pr(θS ∈ C(x)). Table 7.1 shows the
coverage probability of the intervals for k = 3. For CPB(x), a total of 1000 trials were
examined, and for each trial, 1000 bootstrapped samples were calculated. Similar results
for k = 5 are shown in Table 7.2. Included in each of the tables was also the naive confidence
interval of the MLE, (CMLE(x)):
θˆMLE,S ± 1.96
√
σ2
n1 + n2
CPB(x) had coverage probabilities that consistently exceeded the targeted value of 0.95,
suggesting that the intervals were too wide. One explanation for this was the fact that
the distribution of the bootstrapped values for the selected arm consisted of instances
where the arm was carried to stage 2 and those where it was not. In the instances where
the bootstrapped value was based only on a stage 1 estimate, it was likely that it was
an underestimate of the true mean. This would lead to a wider confidence interval. To
have reasonable coverage using this approach, all arms would need to be simultaneously
adjusted.
The interval defined by Sill was the most consistently accurate across all scenarios as all
coverage probabilities were near 0.95. The naive MLE confidence interval was surprisingly
accurate for values of t ≤ 0.50 and k = 3, but was less accurate for k = 5. The coverage
probability of the naive confidence interval decreased, particularly in the Equal Means
scenario, as the selection times were later in the study and the number of arms increased.
A summary of the width of the confidence intervals is found in Figure 7.1 for k = 3
and t = 0.5. The width of CMLE(x) was constant as it was 2 ∗ (1.96σ/
√
n1 + n2) = 0.392
for all observations. The relative widths of CPB(x) and CSill(x) depended on the scenario.
Even though the coverage of CPB(x) exceeded the target value, it had generally narrower
confidence intervals in the Equal Means scenario compared to CSill(x). For the other three
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Selection
Time
CI Equal
Means
Linear
Means
Two Active
Arms
One Active
Arm
0.2
CPB(x) 1.000 0.988 0.995 0.985
CSill(x) 0.950 0.948 0.950 0.950
CMLE(x) 0.943 0.944 0.948 0.949
0.5
CPB(x) 0.993 0.974 0.983 0.951
CSill(x) 0.953 0.953 0.947 0.946
CMLE(x) 0.936 0.950 0.946 0.945
Table 7.1: Comparison of coverage probabilities using various approaches to calculating
confidence intervals in study designs with 3 treatment arms and a normal endpoint. The
results for CPB(x) were based on 1000 simulated trials with 1000 bootstrapped samples in
each trial. The results for CSill(x) and CMLE(x) were based on 10,000 simulated trials.
Selection
Time
CI Equal
Means
Linear
Means
Two Active
Arms
One Active
Arm
0.2
CPB(x) 0.999 0.999 0.998 0.988
CSill(x) 0.951 0.946 0.952 0.946
CMLE(x) 0.934 0.937 0.946 0.938
0.5
CPB(x) 0.986 0.982 0.989 0.963
CSill(x) 0.948 0.949 0.953 0.948
CMLE(x) 0.907 0.932 0.950 0.943
Table 7.2: Comparison of coverage probabilities using various approaches to calculating
confidence intervals in study designs with 5 treatment arms and a normal endpoint. The
results for CPB(x) were based on 1000 simulated trials with 1000 bootstrapped samples in
each trial. The results for CSill(x) and CMLE(x) were based on 10,000 simulated trials.
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Figure 7.1: Comparison of confidence interval widths for study designs with 3 treatment
arms, t=0.5, and a normal endpoint. Only the 1000 studies examined for the bootstrapped
confidence interval were assessed for each of the three intervals.
scenarios, however, CSill(x) had similar or smaller widths in general. In addition, CSill(x)
was easier to compute, giving it an added advantage. Given this ease in computation, its
reasonable width, and the reasonable coverage probability across all values of t, the Sill
confidence interval appeared to be the best option. It was also accurate when the second
best treatment arm was selected as shown in Table 7.3 with k = 5. In calculating this, the
largest stage 1 mean was removed and the confidence interval was calculated based on the
remaining four arms. This prohibited CPB(x) from being used due to the complication
of how to handle bootstrapped samples where the bootstrapped value of the true selected
arm was the largest in stage 1 and was therefore removed.
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Selection
Time
CI Equal
Means
Linear
Means
Two Active
Arms
One Active
Arm
0.2
CSill(x) 0.952 0.952 0.951 0.948
CMLE(x) 0.959 0.955 0.949 0.947
0.5
CSill(x) 0.957 0.951 0.951 0.947
CMLE(x) 0.976 0.958 0.951 0.935
Table 7.3: Comparison of coverage probabilities using the Sill approach to calculating con-
fidence intervals and the naive MLE confidence interval in study designs with 5 treatment
arms and a normal endpoint (second largest stage 1 mean selected). The results were based
on 10,000 simulated trials with a normally distributed endpoint.
7.1.1.3 Assessing New Potential Estimator Based on Sill Confidence Interval
Given how well the confidence interval proposed by Sill performed, it was of interest to
understand whether an improved estimator based on f(Z|Q,XC , θS) could be identified,
where:
f(Z|Q,XC , θS) = CNφ
[
Z − (n1 + n2)θS
σ
√
n1 + n2
]
Φ
[√
n1Z − (n1 + n2)X2
σ
√
n2(n1 + n2)
]
A closer look at the distribution showed that it was a function of a normal distribution
(φ [·], denoted as f(Z|θS)). This normal distribution was multiplied by a factor equal to
the probability of observing a smaller difference between θˆMLES and X2, defined by Φ [·].
As can be seen in Figure 7.2, there were some distinct characteristics of f(Z|Q,XC , θS).
When the difference between θˆMLE,S and X2 was large, then f(Z|Q,XC , θS) was nearly
equivalent to f(Z|θS) because Φ [·] was nearly 1 for all values of Z. Conversely, when the
difference was small, then f(Z|Q,XC , θS) was shifted to have a larger expectation than
f(Z|θS). The value of t could also impact this distribution. So f(Z|Q,XC, θS) could differ
drastically depending on X2, even with constant Z and t.
It can therefore be seen that, for f(Z|Q,XC , θS), the expectation of Z alone (uncondi-
tional) was less than or equal to the expectation of Z conditional on X2. In addition, the
maximum likelihood estimate for θS in f(Z|Q,XC, θS) was still θˆMLE,S . Because of this,
using f(Z|Q,XC , θS) to define an estimator would not result in any improved performance
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Figure 7.2: Characteristics of f(Z|Q,XC , θS) with n1 + n2 = 100. a) Distribution of φ [·]
with θS = 0.4. b) The function Φ [·] when n1 = n2 = 50 and X2 = 0 (solid), 0.2 (dashed),
0.4 (dotted). c) f(Z|Q,XC , θS) when θS = 0.4, n1 = n2 = 50, and X2 values of 0 (solid),
0.2 (dashed), 0.4 (dotted). d) f(Z|Q,XC , θS) when θS = 0.4, X2 = 0.4, and n1 values of
10 (solid), 50 (dashed), 90 (dotted)
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Scenario CI Bias RMSE
Equal Means
Sill Midpt -0.014 0.122
θˆPB,S 0.030 0.094
θˆBG,S -0.000 0.122
Linear Means
Sill Midpt -0.009 0.113
θˆPB,S 0.002 0.100
θˆBG,S 0.001 0.111
Two Active Arms
Sill Midpt -0.010 0.122
θˆPB,S 0.011 0.099
θˆBG,S 0.003 0.122
One Active Arm
Sill Midpt -0.011 0.110
θˆPB,S -0.011 0.109
θˆBG,S -0.004 0.106
Table 7.4: Assessment of Sill confidence interval midpoint as an estimator in study designs
with 3 treatment arms, t = 0.5, and a normal endpoint. The results were based on 1000
simulated trials with a normally distributed endpoint.
with respect to bias and MSE compared to θˆMLE,S . As another option, one could instead
use the midpoint of the Sill confidence interval as an estimator. As shown in Table 7.4,
this did not result in improved bias or MSE compared to other estimators. So for the
purpose of estimation, the parametric bootstrap approach was still preferred, and it was
recommended that it be used in conjunction with the Sill confidence interval. There was
only a small probability that θˆPB,S would fall outside of the Sill confidence interval. In the
above simulation results, this occurred no more than once in 1000 trials in each scenario.
7.1.2 Binomial Endpoints
With normally distributed endpoints, the confidence interval proposed by Sill (2000) had
the most accurate coverage probability. Sill and Sampson (2009) proposed a confidence
interval for the difference between the selected arm and a control arm in a treatment-
selection study with a binomial endpoint that was similar in approach to their interval
for studies with a normal endpoint. They tested the hypotheses H0 : θS − θ0 ≤ ∆10 vs
H1 : θS − θ0 > ∆10. Again assuming Q was the event that X : X1 > X2 > ... > Xk, they
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derived the joint distribution f(X, Y |Q):
f(X, Y |Q) = K(θ)−1IQ(X)
(
n1
XS
)
θXSS (1− θS)n1−XS
(
n2
Y
)
θXSS (1− θS)n1−XSΠ
where
Π =
k∏
i=2
(
n1
Xi
)
θXii (1− θi)n1−Xi .
The Y term was then converted to Z to get:
f(Z,X|Q) = K(θ)−1IQ(X)
(
n1
XS
)(
n2
Z −XS
)
θZS (1− θS)n1+n2−ZΠ,
where Z = XS + Y . XS was then integrated out to get:
f(Z,XC|Q) = K(θ)−1 ∗Π ∗ IQ(XC)θZS (1− θS)n1+n2−Z∗
min(n1,Z)∑
X1=max(X(2)+1,Z−n2)
(
n1
XS
)(
n2
Z −XS
)
They then went on to find the distribution f(Z|∆10,XC, T ) where T = Y0 +Z and Y0 was
the number of responses in the control arm. Just as was done in Sampson and Sill (2005),
they then found a UMPCU test and inverted it to find the appropriate confidence interval.
While the confidence interval that Sill derived in his dissertation was for the selected
arm with a normal endpoint, a similar approach was explored here for binomial endpoints,
although there was no published literature found showing that this had been previously
described. For the purposes of this investigation, a confidence interval for the selected arm
only was based on the distribution f(Z,XC|Q), where K(θ)−1, IQ(X), and Π were included
in the normalization constant CN . To address the fact that the arm with the lower index
was selected when ties occurred, the lower limit of the summation was adjusted per Sill
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and Sampson (2009). The distribution that was used for the confidence intervals was:
f(Z,XC |Q) = CNθZS (1− θS)n1+n2−Z
min(n1,Z)∑
XS=R
(
n1
XS
)(
n2
Z −XS
)
,
where R = max(X(2), X(3), Z − n2) when k = 3 and the first arm was selected, R =
max(X(1) + 1, X(3), Z − n2) when the second arm was selected, and R = max(X(1) +
1, X(2) + 1, Z − n2) when the third arm was selected. A similar limit was used when
k = 5. CN was again calculated separately for a range of θS values. The summation of the
densities for values of Z ranging from X(2) (or X(2) + 1) to n1 + n2 was calculated for each
θS , and CN was assigned the inverse of this value. The “Sill-like” 95% confidence interval
was then the values of θS where Pr(Z ≤ Zobs) = 0.025 and 0.975.
Tables 7.5, 7.6, and 7.7 summarize the coverage probabilities of the “Sill-like” confidence
interval and the exact confidence interval of the MLE using the “binom” R package (Dorai-
Raj (2014)), which made use of the Pearson-Klopper method (Clopper and Pearson (1934))
and was based on a beta distribution:
max(θ : Pr(X ≤ x|Ni, θ) ≤ α/2),min(θ : Pr(X ≥ x|Ni, θ) ≤ α/2)
While the exact confidence interval tended to have coverage probabilities slightly larger
than the targeted 95%, the “Sill-like” confidence intervals had coverage probabilities that
were consistently close to 95%. With only one arm (i.e. no selection of treatment), n =
100, and θ = 0.38, the coverage of the exact confidence interval was approximately 96%.
The fact that the amount of bias observed was relatively small when treatment selection
occurred likely led to only a small drop in this coverage probability. Figure 7.3 shows that
the width of the “Sill-like” confidence interval tended to be slightly wider than the exact
confidence interval, with the exception of the One Active Arm scenario. Taken together,
it appeared that both confidence intervals were reasonable to use for treatment-selection
designs. The narrower width of the exact confidence interval may actually make it slightly
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Selection
Time
CI Equal
Means
Linear
Means
Two Active
Arms
One Active
Arm
0.2
Exact 0.950 0.956 0.969 0.958
Sill-like 0.940 0.947 0.954 0.951
0.5
Exact 0.962 0.961 0.961 0.956
Sill-like 0.954 0.953 0.950 0.953
Table 7.5: Comparison of coverage probabilities using the “Sill-like” approach to calculating
confidence intervals to the exact confidence interval in study designs with 3 treatment arms
and a binomial endpoint. The results were based on 10,000 simulated trials.
Selection
Time
CI Equal
Means
Linear
Means
Two Active
Arms
One Active
Arm
0.2
Exact 0.961 0.951 0.955 0.955
Sill-like 0.951 0.952 0.950 0.948
0.5
Exact 0.940 0.948 0.969 0.951
Sill-like 0.954 0.946 0.956 0.952
Table 7.6: Comparison of coverage probabilities using the “Sill-like” approach to calculating
confidence intervals to the exact confidence interval in study designs with 5 treatment arms
and a binomial endpoint. The results were based on 10,000 simulated trials.
more appealing.
7.2 Including a Futility Analysis at the Interim Analysis
Some treatment-selection designs (e.g. Thall et al. (1988), Kelly et al. (2005), Stallard and
Friede (2008)) have recommended carrying a treatment arm forward to stage 2 only if it
exceeded a clinically meaningful threshold. If no treatments exceeded that threshold, then
the study stopped early for futility. This type of requirement could result in estimated
values that overestimated the true mean by a wider margin because the distribution of the
stage 1 means carried forward to stage 2 would be truncated with lower values removed.
So the performance of θˆMLE,S , θˆPB,S , θˆCB,S , and θˆBGG,S were evaluated in this type of
modified design. Note that θˆBG,S was no longer unbiased (but still had elevated RMSE)
under this condition. This was due to the fact that the estimator was based on the distri-
bution of the stage 2 data conditional on the stage 1 means and the order statistics, and it
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Selection
Time
CI Equal
Means
Linear
Means
Two Active
Arms
One Active
Arm
0.2
Naive Exact 0.959 0.955 0.949 0.947
Sill-like 0.952 0.952 0.951 0.948
0.5
Naive Exact 0.976 0.958 0.951 0.935
Sill-like 0.957 0.951 0.951 0.947
Table 7.7: Comparison of coverage probabilities using the “Sill-like” Approach to Calculat-
ing Confidence Intervals Relative to Naive Confidence Interval when the second best arm
was selected in a design with 5 arms and a binomial endpoint. The results were based on
10,000 simulated trials.
Figure 7.3: Comparison of confidence interval widths in study designs with 3 treatment
arms, t = 0.5, and a binomial endpoint. The results were based on 10,000 simulated trials.
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assumed that all studies carried one arm forward to stage 2. With this particular design,
that assumption was violated, so this estimator was not examined further. The parametric
bootstrap estimate was calculated in a manner similar to that described above, but the
reference distribution was calculated such that only simulated studies where the selected
arm exceeded the futility boundary were included.
Study designs having five experimental treatment arms and one control arm, each with
normally distributed endpoints, were assessed. All arms were assumed to have known
σ2 = 1, and the control arm was assumed to have a mean of 0. If the study did not stop
for futility, the selected arm and the control arm each had a total of 100 patients enrolled
to them. Five different scenarios were examined for the experimental arms, four of which
were the same as previously described:
• Scenario 1 (”Equal Means”): θ = (0.4, 0.4, 0.4, 0.4, 0.4)
• Scenario 2 (”Linear Means”): θ = (0, 0.1, 0.2, 0.3, 0.4)
• Scenario 3 (”Two Active Arms”): θ = (0, 0, 0, 0.4, 0.4)
• Scenario 4 (”One Active Arm”): θ = (0, 0, 0, 0, 0.4)
• Scenario 5 (”Null Means”): θ = (0, 0, 0, 0, 0)
A single treatment arm continued enrollment in stage 2 only if its improvement over the
control arm exceeded some threshold. This threshold was set such that there was only a
25% chance of carrying an arm to stage 2 in the Null Means scenario. For 5 arms, the
study was stopped for futility if:
X(1) −X0√
2σ2/n1
< 1.39
where X0 was the stage 1 mean of the control arm.
Table 7.8 summarizes the probability of stopping for futility in each scenario across
several selection times. Futility was declared 75% of the time in the Null Means scenario
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Selection
Time
Equal
Means
Linear
Means
Two Active
Arms
One Active
Arms
Null
Means
t=0.2 0.208 0.403 0.376 0.509 0.757
t=0.3 0.129 0.295 0.261 0.401 0.754
t=0.4 0.074 0.225 0.190 0.324 0.754
t=0.5 0.046 0.170 0.133 0.260 0.750
Table 7.8: Probabilities of stopping for futility in study designs with normal endpoints.
as designed. The scenarios with the fewest number of active arms, the One Active Arm
scenario, had higher probabilities of stopping for futility. The probability of stopping early
for futility was lowest in the Equal Means scenario as that had the largest number of arms
with an active treatment. Overall, the probabilities of stopping for futility were fairly high
when there were active treatment arms, suggesting that the futility boundary was likely
too high. While a real study might have a lower boundary, the design described above was
used to clearly illustrate the impact of the futility analysis on estimation.
The performances of the estimators in this design are summarized for the first four
scenarios in Figure 7.4. Note that this summarizes the results conditional on the study
proceeding past the futility analysis. The MLE yielded the worst bias in all four scenarios
and had elevated RMSE in all scenarios except the One Active Arm scenario. The bias
of the parametric bootstrap estimator was lower than any of the other estimators. This
decreased bias did seem to come at the expense of slightly higher RMSE, particularly in
the Equal Means scenario and to a lesser extent in the One Active Arm scenario.
Table 7.9 summarizes the estimates in the Null Means scenario. While the relative
pattern was similar to the Equal Means scenario, the magnitude of the bias for all four
estimators was larger. While there was a small penalty paid for the reduced bias in the
form of a slight increase in RMSE under some scenarios, the results taken together did
suggest that the parametric bootstrap estimator could be successfully extended to designs
with a futility analysis.
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Figure 7.4: Bias of estimators in study designs with 5 treatment arms and a futility anal-
ysis (normal endpoint). Results are conditional on the study proceeding past the futility
analysis
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Bias RMSE
MLE PB CB BGG MLE PB CB BGG
t=0.2 0.077 0.044 0.050 0.054 0.121 0.104 0.106 0.097
t=0.5 0.116 0.063 0.073 0.075 0.143 0.108 0.113 0.106
Table 7.9: Bias and RMSE of estimators under Null Means Scenario in study designs with
5 treatment arms, a futility analysis, and a normal endpoint.
7.3 Selecting More than One Arm for Stage 2
The parametric bootstrap estimator was also evaluated in an extension of the design de-
scribed above. This study design included a futility analysis, but also allowed for two arms
to be selected to continue to stage 2 if both arms met the criteria that
X(i) −X0√
2σ2/ni
≥ 1.39.
The arm with the largest mean at the end of stage 2 was then selected.
To accommodate this design, the parametric bootstrap estimator needed to again be
modified. At the end of stage 1, the pˆ(1)i values were calculated in the usual manner. If one
arm was selected for stage 2, then the estimator was calculated as previously described. If
two arms were selected, then let the pˆ(1)i value for the arm with the largest mean be denoted
as pˆ(1)S1 and as pˆ(1)S2 for the arm with the second largest mean. Let ζ = pˆ(1)S1 + pˆ(1)S2
be the combined probability of selection. Let qˆ(1)1 and qˆ(1)2 be the estimated probability
that each arm in stage 2 was the one selected at the final analysis, based only on the stage
2 data. This was calculated in the same manner as pˆ(1)i. Only the stage 2 data was used
for the calculation of qˆ(1)1 and qˆ(1)2 to ensure that the distribution of each arm remained
independent and normal.
The final probability of each of the stage 2 arms being the one with the largest mean
was:
rˆ(1)i = tpˆ(1)i + (1− t)ζqˆ(1)i.
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The value qˆ(1)i was multiplied by ζ so that the sum of the stage 1 and stage 2 probabilities
for the two selected arms was constrained to ζ, and the sum of the probabilities across all
arms remained equal to 1. At the end of the study, the probability of the stage 1 arms not
selected remained the same, while the proportion of ζ assigned to each of the two selected
arms could vary based on the stage 2 data.
As an example, assume the stage 1 means were such that X1 > X2 > X3 > X4 > X5,
then the final set of probabilities, p˜(1), would be:
p˜(1) = (rˆ(1)1, rˆ(1)2, pˆ(1)3, pˆ(1)4, pˆ(1)5).
When calculating the final adjusted estimate, the different total number of patients in each
arm, Ni, needed to be taken into account, so it was calculated as:
θˆPB,S =

∑k
i=1NiGi∑k
i=1Ni
if η > ηc
(1− η)
∑k
i=1Nip˜(1)iGi∑k
i=1Nip˜(1)i
+ η
∑k
i=1NiGi∑k
i=1Ni
if η ≤ ηc
where Gi was the MLE of each arm based on all available data. The linear combination
was denoted in the form
∑k
i=1Nip˜(1)iGi∑k
i=1Nipˆ(1)i
to account for the different number of patients in
each arm. Failure to do this would result in the assignment of too much weight to the arms
that stopped in stage 1.
Here, η was calculated based on p˜(1), so the reference distributions used to calculate η
was also modified. Three separate reference distributions were generated:
• One distribution for when the stage 1 mean of only one arm exceeded the futility
boundary. For this distribution, simulations where no arms exceeded the futility
boundary or where two or more arms exceeded it were removed. The Euclidean
distances were calculated based on the simulated pˆ(1)i values.
• One distribution for when the stage 1 mean of two arms exceeded the futility bound-
ary, and the arm with the largest stage 1 mean was selected at the end of stage 2.
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The Euclidean distances were calculated based on the simulated p˜(1) values.
• One distribution for when two arms exceeded the futility boundary, and the arm with
the second largest stage 1 mean was selected at the end of stage 2. The Euclidean
distances were calculated based on the simulated p˜(1) values.
Table 7.10 summarizes the probability of selecting two arms to stage 2. Not unex-
pectedly, the probability was the highest in the Equal Means scenario since all arms had
large true means. The probability was also elevated in the Linear Means and the Two
Active Arms scenarios. Table 7.11 shows that there was only a small improvement in the
probability of selecting the correct arm when allowing two arms to move forward compared
to when only one arm was allowed, as observed in Table 7.8. The improvement was the
largest in the Linear Means scenario or when the treatment selection time was early in the
study. The increase in this probability would likely be larger if the futility boundary was
lower (i.e. less likely to declare futility).
Figure 7.5 shows the performance of θˆMLE,S , θˆBGG,S and θˆPB,S when using this de-
sign. The bias of θˆMLE,S was slightly larger when two arms were allowed to be selected
compared to Figure 7.4 with the exception of the One Active Arm scenario. θˆPB,S was
still substantially lower than θˆMLE,S with respect to bias, and it only showed a marginal
increase compared to the design that allowed only one arm to be selected for stage 2. In the
Equal Means, Linear Means, and Two Active Arm scenarios, θˆPB,S also had much lower
RMSE. θˆPB,S also showed improved bias in all four scenarios compared to θˆBGG,S . Table
7.12 also showed that θˆPB,S had bias that was almost 50% lower than θˆMLE,S in the Null
Means scenario. Taken together, this illustrated that θˆPB,S could be just as effective when
it was extended to designs that allowed multiple arms to be selected after stage 1.
7.4 Time-To-Event Endpoints
A treatment-selection design for time-to-event endpoints was described by Schaid et al.
(1990), and it was assumed that a bias similar to that described above would be observed
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Selection
Time
Equal
Means
Linear
Means
Two Active
Arms
One Active
Arms
Null
Means
t=0.2 0.610 0.342 0.336 0.179 0.098
t=0.3 0.740 0.440 0.438 0.193 0.096
t=0.4 0.823 0.500 0.526 0.206 0.100
t=0.5 0.882 0.583 0.606 0.207 0.102
Table 7.10: Probabilities of selecting two arms for stage 2 in study designs with a normal
endpoint and a futility analysis.
Linear Means Two Active Arms One Active Arm
1 Arm 2 Arms 1 Arm 2 Arms 1 Arm 2 Arms
t=0.2 0.298 0.358 0.584 0.610 0.394 0.434
t=0.3 0.404 0.467 0.717 0.736 0.535 0.566
t=0.4 0.464 0.523 0.796 0.808 0.628 0.656
t=0.5 0.513 0.584 0.858 0.866 0.707 0.730
Table 7.11: Probabilities of selecting correct arm in study designs with a normal endpoint
and a futility analysis where only one arm was allowed to move on to stage 2 compared to
when two arms were allowed.
Bias RMSE
MLE BGG PB MLE BGG PB
t=0.2 0.090 0.055 0.047 0.126 0.096 0.101
t=0.5 0.130 0.079 0.072 0.151 0.109 0.107
Table 7.12: Bias and RMSE of estimates under Null Means scenario in study designs with
5 treatment arms, a normal endpoint, and two arms may be selected for stage 2.
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Figure 7.5: Bias and RMSE of estimators in study designs with 5 treatment arms, a futility
analysis, and two arms can move to stage 2 (normal endpoint).
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with this type of endpoint as well. While there are complexities in using a treatment-
selection design with time-to-event endpoints, addressing these issues was outside the scope
of this dissertation. The purpose here was to assess whether θˆPB,S could potentially be
extended to time-to-event endpoints. The summary statistic of interest was the hazard
ratio between the treatment arm of interest and the control arm, so the first issue that
needed to be addressed was how to adjust the stage 1 hazard ratio. The log hazard ratio
comparing arm i to the control, θˆi, had a distribution that was approximately normal with
mean θi and variance
4
di
, where di is the total number of events observed in arm i and the
control arm combined. The value 4di is the variance of θi under the null hypothesis, but
holds as a reasonable approximation when θi is close to 0. The log hazard ratio can be
normalized using a Wald statistic:
Z
(w)
i =
θˆi√
4
di
,
where Z
(w)
i ∼ N(0, 1) under the null hypothesis of no difference between arm i and the
control (i.e. θi = 0).
With this in mind, a modified parametric bootstrap estimator was evaluated for use
in a treatment-selection design with time-to-event endpoints. The value θˆi was estimated
for each arm using the Cox proportional hazard model at the end of stage 1. The Wald
statistic of each arm, Z
(w)
i , was then calculated and used to derive the pˆ(1)i values as
previously described, assuming a normal distribution for Z
(w)
i . The pˆ(1)i values were then
compared to the corresponding reference distribution to determine the null probability η.
The reference distribution was generated by assuming that all k arms had Wald statistics
that were distributed as N(0, 1).
The weight assigned to each arm was then calculated:
w∗i =
η
k
+ (1− η)pˆ(1)i
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In the case of time-to-event endpoints, the purpose of the weights was to assign them to
each patient in a treatment arm, and then a single adjusted hazard ratio was calculated
using a weighted Cox proportional hazard model. For this particular weighted model, all
patients in the k treatment arms were assumed to be assigned to the same arm, so the
model output would be a single weighted average hazard ratio across all arms. In order for
this to occur, the weights needed to be adjusted further. In all instances, the weight of the
control-arm patients was set to 1. If η was large (i.e. each arm had similar probabilities of
being the one with the largest Wald statistic), the weights of each treatment arm needed
to be close to 1. If η was small, only the weight of the treatment arm with the largest
Wald statistic needed to be 1 while the others approached 0. To achieve this, the weights
were adjusted to be:
wij =
 1 if patient j was enrolled to control armmax(0.000001, w∗imax(w∗1 ,...,w∗k)) otherwise
The value 0.000001 was used because all weights were required to be greater than 0 in the
model. The adjusted stage 1 Wald statistic, Z˜
(w,1)
S , was then calculated as:
Z˜
(w,1)
S = θˆ
(1)
PB,S
√
d1,S
4
where θˆ
(1)
PB,S was the log hazard ratio from the weighted Cox proportional hazard model
and d1,S was the number of total events in the selected arm and the control arm.
A method was then needed to identify the stage 2 estimate. Typically, a hazard ratio
is calculated at the interim analysis and again at the final analysis, where the final analysis
includes the data from the entire study. Unlike the normal and binomial endpoints, one
cannot calculate a hazard ratio based only on the stage 2 patients and then combine the
stage 1 and stage 2 results. Many patients enrolled in stage 1 may not have an event until
stage 2 patients are enrolling. It has been shown, however, that the log hazard ratio can
also be standardized using a score statistic, Z
(s)
i = Iiθˆi where Ii =
di
4 is the information of
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the estimate under the null hypothesis (Jennison and Turnbull (2000)). This test statistic
also has a normal distribution, Z
(s)
i ∼ N(Iiθi, Ii), and it can be shown to result in the same
test statistic as the Wald statistic:
Z
(s)
i =
Si√
Ii
= θˆi
√
Ii =
θˆi√
4
di
.
Let Z(s,1) be the score statistic at an interim analysis, and Z(s,F ) be the score statistic at
the final analysis. Tsiatis (1981) showed that when patients were assigned to a treatment
randomly during a study, Z(s,1) and Z(s,F ) − Z(s,1) had an asymptotic covariance of 0,
so they were independent increments. This supported the use of group sequential designs
with time-to-event endpoints. It can be shown that E[Z(s,F ) − Z(s,1)] = (IF − I1)θ, where
θ was the true log hazard ratio and I1 and IF were information for the stage 1 and final
estimate, respectively. In addition:
V ar
(
Z(s,F ) − Z(s,1)
)
= V ar
(
Z(s,1)
)
+ V ar
(
Z(s,F )
)
− 2Cov
(
Z(s,1), Z(s,F )
)
= I1 + IF − 2I1
= IF − I1.
So Z(s,F ) − Z(s,1) ∼ N((IF − I1)θ, IF − I1), and this can be converted into an incremental
score (or Wald) statistic:
Z(2) =
√
dFZF −
√
d1Z1√
dF − d1
.
where Z1 and ZF were the score statistics at stage 1 and the final analysis, respectively,
and d1 and dF were the number of events. Note that since it was shown that the score
statistic and the Wald statistic were the same, there was no need to denote the type of
statistic in the notation.
The identification of Z(2) allowed for an arrangement of the time-to-event data that was
similar to that of normal and binary endpoints. Using this set-up, there was an adjusted
stage 1 estimate, Z˜
(1)
S , and an incremental stage 2 estimate, Z
(2)
S for the selected arm. The
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final adjusted log hazard ratio was then calculated as:
θˆPB,S =
(√
d1,S
d1,S + d2,S
Z˜
(1)
S +
√
d2,S
d1,S + d2,S
Z
(2)
S
)√
4
d1,S + d2,S
To investigate the performance of the parametric bootstrap estimator, a series of sim-
ulations were conducted examining designs with time-to-event endpoints. Each simulated
study had five experimental arms and one control arm, and the total number of events
(both stage 1 and stage 2) required in the selected arm and the control arm combined was
set at 191 events. Assuming an exponential survival function, this provided 80% power to
detect a hazard ratio of 1.5 when the control arm had an assumed median time-to-event
of 10 months.
For time-to-event endpoints, the power of the study and the information fraction of
an interim analysis are generally determined by the number of events, but in the design
proposed by Schaid et al., the timing of the interim analysis was instead based on the
number of patients enrolled. Because of this, the number of observed events that drove
the selection decision would be dependent, in part, upon the enrollment rate. With slower
enrollment rates, the additional time needed to enroll the necessary number of patients
allowed for more events to be observed by the time of the interim analysis. This relationship
needed to be considered when evaluating the estimators, so two different enrollment rates
were considered (8.5 and 19.3 patients per month), with the anticipated follow-up period
for the selected arm and the control arm fixed. The control arm was assumed to have a
median time-to-event of 10 months. For simplicity, it was assumed that no patients were
censored for loss to follow-up, so the total enrollment in the selected arm and control arm
combined (1:1 randomization) was 254 and 290 patients for the slow and fast enrollment,
respectively. The following four scenarios were examined:
• Scenario 1 (“Equal HR”): θ = log(1.5, 1.5, 1.5, 1.5, 1.5)
• Scenario 2 (“Linear HR”): θ = log(1, 1.106, 1.224, 1.355, 1.5)
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Linear HR Two Active Arms One Active Arm
15 months 30 months 15 months 30 months 15 months 30 months
t=0.2 0.316 0.362 0.676 0.751 0.430 0.510
t=0.3 0.382 0.443 0.798 0.882 0.558 0.676
t=0.4 0.456 0.502 0.893 0.936 0.701 0.786
t=0.5 0.517 0.558 0.948 0.973 0.817 0.882
Table 7.13: Probabilities of selecting correct arm in study designs with time-to-event end-
points. In this case, the treatment selection time was based on number of patients, not
number of events. Two different enrollment periods were compared (15 and 30 months)
• Scenario 3 (“Two Active Arms”): θ = log(1, 1, 1, 1.5, 1.5)
• Scenario 4 (“One Active Arm”): θ = log(1, 1, 1, 1, 1.5)
Note that Scenario 2 was linear in terms of the log hazard ratio. The selection time values,
t, ranged from 0.2 and 0.5, where t was the percentage of total patients enrolled to the
selected arm. Table 7.13 shows the probabilities of selecting the correct arm in Scenarios
2 through 4. These probabilities were lower than either the normal or binomial endpoints,
particularly with the faster enrollment rate due to the reduced time to observe events. In
the case of the Linear HR scenario, the probability of selecting either of the top two arms
was 79% for fast enrollment and 84% for slow enrollment when t = 0.5.
Figure 7.6 shows the distribution of the number of events at the interim analysis for the
Equal Means scenario. Note that other scenarios exhibited very similar distributions. At
t = 0.2, the average information fraction (the percentage of the 191 total events observed
at the interim analysis) was 4% for the faster enrollment and 6% for the slower enroll-
ment. Similarly, at t = 0.5, the information fraction was 27% and 38% for the faster and
slower enrollment, respectively. So the amount of information used to calculate the hazard
ratio was less than t, which explained the lower probabilities of selecting the correct arm
compared to normal and binomial endpoints. It also suggested that a very early interim
analysis around t = 0.2 was not recommended due to limited information, unless additional
information was used in the selection decision.
Figures 7.7 and 7.8 show the performance of θˆPB,S compared to the unadjusted log
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Figure 7.6: Distribution of events (selected arm and control arm combined) observed at
the interim analysis for selection times of t = 0.2 and t = 0.5 in study designs with a
time-to-event endpoint. Solid lines represent the fast enrollment rate, and dashed lines
represent the slow enrollment rate.
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hazard ratio. The bias was, in general, slightly higher with slower enrollment. This was
due to the fact that the stage 1 estimate was based on a larger number of events, so the
information fraction was higher. As was previously observed with normal and binomial
endpoints, larger information fractions tended to lead to increased bias relative to smaller
information fractions. It also appeared that the bias and RMSE of θˆPB,S behaved differ-
ently at t = 0.20. This was also likely due to the limited number of events at the interim
analysis.
Overall, θˆPB,S adjusted the estimate very well with respect to bias and RMSE in the
Equal HR, Linear HR, and Two Active Arms scenarios. Similar to normal endpoints, θˆPB,S
tended to overcorrect in the One Active Arm scenario with an elevated RMSE, but the
largest absolute bias was -0.029 at t = 0.5 with the slower enrollment. This represented an
observed hazard ratio of 1.457 instead of 1.5, so the level of over-correction in the worst of
the scenarios was much less than the bias often observed with the unadjusted estimator.
In terms of RMSE, when the selection time was at 0.3 or later, θˆPB,S had lower or similar
values. Taking these results as a whole, this demonstrated that the parametric bootstrap
estimator could also be extended to time-to-event endpoints.
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Figure 7.7: Bias and RMSE of estimators in study designs with 5 treatment arms, a time-
to-event endpoint, and fast enrollment.
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Figure 7.8: Bias and RMSE of estimators in study designs with 5 treatment arms, a time-
to-event endpoint, and slow enrollment.
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Chapter 8
Summary and Discussion
Adaptive designs can potentially improve the efficiency of the drug development process
by allowing researchers to make changes to the design based on emerging data. Further de-
velopment of some designs, however, is required before they are more widely implemented.
In the case of treatment-selection designs, a number of approaches have been proposed
for controlling the Type I error rate, but an issue that remains is the bias of the point
estimate resulting from the selection method. While estimators have been proposed that
are conditionally unbiased, these approaches tend to have large RMSE under a number of
scenarios. Other methods, such as shrinkage and empirical Bayes estimators that allow for
the acceptance of a small amount of bias in exchange for reduced RMSE, have also been
proposed. These methods, however, had other shortcomings in that the absolute bias was
unacceptably high when there were only a limited number of active arms.
Two new bias-adjusting methods were proposed in this dissertation. One was an em-
pirical Bayes estimator that included limited translation to minimize the chance for over-
correction of the bias. The extent of limited translation was determined by a function of
the differences among all treatment arms and was only applied when the difference between
the selected arm and the arm with the next largest mean was large. For both normal and
binomial endpoints, this estimator performed well when all arms were equally active, but
had elevated RMSE in several scenarios and was not pursued further.
The other estimator that was proposed made use of parametric bootstrap resampling,
and it was more effective at adjusting the bias while maintaining a reasonable RMSE. It
had a consistently low maximum value for RMSE compared to the other estimators in the
scenarios examined (k between 2 and 5). It also had consistently small maximum bias in the
same scenarios, although a uniformly minimum variance conditionally unbiased estimator
also existed that had better bias adjustment (but much worse RMSE). Its performance was
similar to previously proposed shrinkage estimators, such as the one proposed by Carreras
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and Brannath, but the parametric bootstrap approach had minimal over-correction in the
scenario when there was only one active arm. The parametric bootstrap approach also
had very similar performance to the proportional prior empirical Bayes method that was
proposed by Bowden et al. and was based on meta analysis approaches. While either
θˆPB,S or θˆBGG,S would be reasonable to use with normally distributed endpoints, the
lower general RMSE of the parametric bootstrap estimator and the lower RMSE when the
incorrect arm was selected made it slightly more appealing. An added advantage of the
parametric bootstrap approach was its flexibility in that it could also be extended to apply
to designs with binomial and survival endpoints, studies with futility analyses, and studies
where more than one arm is selected for stage 2.
The parametric bootstrap estimator can also be extended to provide estimates for other
arms, such as those with the second largest mean. There are at least two options for the
estimator in this situation: a) investigators could generate a new reference distribution for
the jth largest stage 1 mean when all k arms have equal true means; or b) investigators
could ignore the arms that were larger than the jth largest and analyze the data as if there
were only a total of j arms. Both options require a new reference distribution since the jth
largest mean cannot exceed the arms with larger means. It is recommended that the latter
option is followed, as the first option does not result in sufficient adjustment for bias. The
reason for this can be seen by an example where the arm with the second largest mean is
of interest. The pˆ(k−1)i values would represent the probability that each arm was selected
as the arm with the second largest stage 1 mean. This probability would often be non-zero
for the arm with the largest mean, so when θˆ1PB,S was calculated, the largest observed
mean would have some contribution, which would negate a portion of the necessary bias
adjustment. It would instead be recommended that the largest mean be removed, and the
adjustment conducted as if there were k−1 arms in the study. There were some scenarios,
however, that were difficult for all examined estimators to accurately adjust the bias, such
as the Two-Active arms scenario. In this scenario, since the second-best arm had the
same true mean as the largest, the observed mean of the second-best arm was likely an
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underestimate, so any bias adjustment would only make the estimate less accurate.
The performance of any estimator must be balanced across various scenarios. If one
wants to reduce the bias of the point estimate when all treatment arms are equal, then
it generally comes with an overcorrection for the bias when there are true differences
between the treatment arms. The ability to specify ηc with the parametric bootstrap
estimator provides flexibility to investigators in that they can identify specific conditions
where bias adjustment should be optimized, so ηc can be set accordingly. Decreasing ηc
results in the grand mean being used for the estimate θˆ1PB,S more frequently. When there
are no differences among the means, this results in lower bias and RMSE. When there
are differences, however, the lower value of ηc results in additional over-correction of the
bias and a high RMSE. This property stems from the fact that the observed results can
provide only limited insight into the true underlying means. A set of treatment means
observed when all true treatment means were equal could also be observed if there were
truly differences among the arms. As a result, having more stringent bias adjustment would
improve the performance when these means were observed in the Equal Means scenario,
but would lead to overcorrection in the One Active Arm scenario. There is no other way
to distinguish between the scenarios when the size of the study is fixed. Increasing the
size of the study, while keeping t constant, or moving the selection time to be later in the
study would better separate the observed data in those two scenarios, but such an approach
would also minimize the advantages of a treatment-selection design.
Estimates of the variability in the adjusted mean are also critical. A confidence interval
based on bootstrap methodology was examined for θˆPB,S . While the width of the confidence
interval was generally reasonable, the coverage probabilities were larger than the targeted
0.95 in studies with normal endpoints. The confidence interval proposed by Sill, which
was based on the exact distribution of the stage 2 mean given all stage 1 means and their
order statistics, was quite accurate with respect to coverage probabilities and had relatively
narrow widths. It was proposed that a confidence interval based on this distribution be
used when a design has either a normal or binomial endpoint. For binomial endpoints, the
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exact confidence interval was also reasonable.
In the results described here, the Euclidean distance was used to calculate the distance
of the pˆ(k)i values from (1/k, ..., 1/k) Other distance measures (e.g. L1 or L3 distances) were
also examined and the results were largely consistent. Differences in the estimate values
using different distance measures were relatively minimal as long as the rank ordering of
the ν∗ values was largely preserved.
It was assumed here that the variance of a normally distributed endpoint was known,
but the parametric bootstrap resampling method could also be implemented with unknown
variance. In this case, the reference distribution would need to be generated after the stage
1 data was collected. The distribution would still be generated assuming equal means
for all treatment arms, but the observed variance for each arm could instead be used.
Alternatively, and if reasonable, the observed pooled variance across all arms could be
used. This would lead to bias adjustment similar to the known variance case, but the
RMSE would be elevated to some degree.
A parametric bootstrap resampling approach was investigated because the treatment
means were resampled (instead of the individual observations), so the central limit theorem
made a normal assumption reasonable. Assumptions about the distribution were made at
two points in the estimation process. The first was in the integrand when calculating
the pˆ(1)i values, and the other was when generating the simulated trial means that led to
each individual ν∗ value which comprised the reference distribution. One could instead
use a nonparametric resampling approach to calculate each of these. To calculate the pˆ(1)i
values, the observed individual values of each arm could be resampled with replacement
separately and new means could be calculated for each arm. If this was repeated a number
of times, one could then calculate the proportion of simulations that each arm was found to
be the largest and use that for pˆ(1)i. Similarly, for the reference distribution, all observed
observations across all arms could be pooled together. Resampled data representing k
treatment arms with n1 observations could then be generated from this pool and the ν
∗
value could be calculated. With a minimum of approximately 30-40 patients per arm at
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the end of stage 1, the differences between the parametric and nonparametric resampling
results were minimal. This suggested that either approach could be used if only one arm was
carried forward after stage 1. Similar adjustments would be required to the nonparametric
resampling framework if a futility analysis was inserted or if multiple arms were carried
forward to stage 2.
Estimation is more complex in treatment-selection studies with time-to-event endpoints.
Special consideration may need to be taken in designing the study to ensure the Type I
error rate is controlled when the p-values from the two stages are combined. Jenkins
et al. (2011) discussed that the treatment-selection decision could be largely driven by
early events in stage 1. In order for the stage 1 and stage 2 p-values to be independent,
the duration of follow-up in the stage 1 patients needed to be pre-specified prior to the
treatment selection. In these studies, it is unlikely that all patients will have an event
prior to the treatment selection time point. The selection will be based primarily on the
proportion of early events across the arms, which may not necessarily lead to the selection
of the best arm. One could try to predict the number of events observed in each of the
arms at a later time point using a method such as that proposed in Bagiella and Heitjan
(2001). While this would attempt to incorporate some of the later events into the decision
making, the limited numbers of events in each arm would likely require some parametric
assumptions, which may have questionable accuracy. In addition, it is possible that one or
more arms may have no observed events by the selection time point, preventing an accurate
summary statistic from being used. So simulations should be used to ensure, with high
probability, that there will be a minimum number of events in each arm at the selection
time point. Alternatively, a surrogate marker could be used to select the stage 2 treatment
arm. Carreras et al. (2015) discussed a case-study where pharmacokinetic exposure was
used, but a biomarker or pharmacodynamic marker or a shorter time-to-event endpoint
(such as progression free survival instead of overall survival) could be used. Use of any
surrogate marker requires high correlation with the primary endpoint to be effective.
There are also some additional considerations that should be made when conducting a
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study with a treatment-selection design. Typically there is a lag between the data cutoff for
an interim analysis and when the actual decision on which arm (or arms) to move forward
with is made. This allows for data cleaning as well as potentially scheduling a meeting
with the IDMC, particularly if the study is blinded with a control arm. As a result, it
is possible to have over-enrollment to the arms that are not selected for stage 2, so care
should be taken to minimize this over-enrollment.
The methodology proposed in this dissertation was intended for a classic treatment-
selection (i.e. Pick-A-Winner or Drop-The-Losers) design, and it was assumed that the
adjusted estimate was calculated post hoc after all hypothesis testing was conducted. It
can be applied both when one or more arms are carried forward to stage 2, and it can
be applied to a number of types of endpoints (normal, binomial, time-to-event, etc). In
its current form, however, the parametric bootstrap estimator cannot be used in a design
where the endpoint differs between stage 1 and stage 2, or when data from multiple sources
(e.g. biomarker data and primary endpoint data) are used to make a decision for stage
2 as in Wang (2014) and Carreras et al. (2015). The proposed estimator also cannot be
used under its current configuration when new arms are added after stage 1 as in Chang
and Wang (2014). Further development would be needed to account for these more recent
adaptations.
While the parametric bootstrap approach does not have minimum variance among
conditional unbiased estimators as those proposed by Bowden and Glimm or Tappin, nor
does it minimize Bayes risk with respect to normally distributed priors as the approach
proposed by Carreras and Brannath, it does possess a performance that strikes a reasonable
balance between bias and mean squared error. Its flexibility in its ability to be used with
various designs and endpoints makes it even more attractive. These reasons make it a viable
option for investigators to use when conducting treatment-selection designs. Advancements
such as this will hopefully lead to greater use of adaptive designs and help to improve the
efficiency of the drug development process.
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